D. Nicolau

发表

Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes.

Christina A. Sutherland, D. Nicolau, 2016, Journal of chromatographic science.

In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa from Pediatric Cystic Fibrosis Patients

Christina A. Sutherland, D. Nicolau, Aimee M. Dassner, 2016, Infectious Diseases and Therapy.

Chylous transport of amiodarone.

C. Strange, D. Nicolau, S. R. Dryzer, 1992, Chest.

Efficacy of Humanized Carbapenem Exposures against New Delhi Metallo-β-Lactamase (NDM-1)-Producing Enterobacteriaceae in a Murine Infection Model

P. Nordmann, D. Nicolau, D. Wiskirchen, 2013, Antimicrobial Agents and Chemotherapy.

Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials

D. Nicolau, David P Nicolau, A. Thabit, 2015, Expert opinion on pharmacotherapy.

Unexpected In Vivo Activity of Ceftazidime Alone and in Combination with Avibactam against New Delhi Metallo-β-Lactamase-Producing Enterobacteriaceae in a Murine Thigh Infection Model

D. Nicolau, J. Crandon, S. MacVane, 2014, Antimicrobial Agents and Chemotherapy.

Clinical and economic implications of urinary tract infections

D. Nicolau, Samantha N. Steiger, Rachel R Comito, 2017, Expert review of pharmacoeconomics & outcomes research.

Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections.

D. Nicolau, 2002, The Journal of antimicrobial chemotherapy.

Antibacterials for the Prophylaxis and Treatment of Bacterial Endocarditis in Children

D. Nicolau, R. Quintiliani, C. Nightingale, 2001, Paediatric drugs.

Determination of Tissue Penetration and Pharmacokinetics of Linezolid in Patients with Diabetic Foot Infections Using In Vivo Microdialysis

D. Nicolau, D. Wiskirchen, Ashley K. Shepard, 2011, Antimicrobial Agents and Chemotherapy.

Tissue Penetration and Pharmacokinetics of Tigecycline in Diabetic Patients with Chronic Wound Infections Described by Using In Vivo Microdialysis

Christina A. Sutherland, D. Nicolau, D. Wiskirchen, 2010, Antimicrobial Agents and Chemotherapy.

In Vivo Microdialysis Study of the Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy Volunteers

Christina A. Sutherland, D. Nicolau, Aryun Kim, 2008, Antimicrobial Agents and Chemotherapy.

Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing.

D. Xuan, D. Nicolau, C. Nightingale, 2004, International journal of antimicrobial agents.

In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam–β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model

C. Bissantz, D. Nicolau, S. Giovagnoli, 2018, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic Evaluation of Meropenem and Cefotaxime for Pediatric Meningitis

D. Nicolau, J. Kuti, J. Ellis, 2006, Paediatric drugs.

Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.

D. Nicolau, J. Kuti, E. Ludwig, 2006, International journal of antimicrobial agents.

The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.

R. Masterton, D. Nicolau, P. Turner, 2005, The Journal of antimicrobial chemotherapy.

Derivation of Meropenem Dosage in Patients Receiving Continuous Veno-Venous Hemofiltration Based on Pharmacodynamic Target Attainment

D. Nicolau, J. Kuti, 2005, Chemotherapy.

Making the most of surveillance studies: summary of the OPTAMA Program.

D. Nicolau, J. Kuti, 2005, Diagnostic microbiology and infectious disease.

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.

G. Drusano, D. Nicolau, J. Kuti, 2004, Clinical therapeutics.

Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.

D. Nicolau, C. Mendes, C. Kiffer, 2004, Diagnostic microbiology and infectious disease.

Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa

D. Nicolau, C. Nightingale, J. Kuti, 2004, Pharmacotherapy.

Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling

D. Nicolau, 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.

D. Nicolau, R. Quintiliani, C. Nightingale, 2002, Diagnostic microbiology and infectious disease.

Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.

D. Nicolau, P. Ambrose, 2001, The American journal of medicine.

Pharmacodynamic Comparisons of Levofloxacin, Ciprofloxacin, and Ampicillin against Streptococcus pneumoniae in an In Vitro Model of Infection

D. Nicolau, R. Quintiliani, C. Nightingale, 1999, Antimicrobial Agents and Chemotherapy.

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.

D. Nicolau, C. Nightingale, Collin D. Freeman, 1997, The Journal of antimicrobial chemotherapy.

A New Progestin Implant (Implanon) for Long-Term Contraception

D. Nicolau, Charles H. Nightingale, David P. Nicolau, 2007 .

Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.

D. Nicolau, C. Mendes, C. Kiffer, 2006, International journal of antimicrobial agents.

Pharmacodynamic Comparison of the Carbapenems Against E. coli and Klebsiella spp. Containing Extended spectrum β-lactamases

D. Nicolau, J. Kuti, K. Eagye, 2005 .

A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway.

M. Boermeester, K. Itani, Yonghong Xiao, 2017, Surgical infections.

Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects

G. Dimopoulos, D. Matthaiou, D. Nicolau, 2017, Drugs.

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

N. Kaplan, D. Nicolau, M. Banevicius, 2013, Journal of chemotherapy.

Activities of liposome-encapsulated azithromycin and rifabutin compared with that of clarithromycin against Mycobacterium avium-intracellulare complex in human macrophages.

D. Nicolau, R. Quintiliani, C. Nightingale, 1994, International journal of antimicrobial agents.

Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages

D. Nicolau, R. Quintiliani, C. Nightingale, 1994, Antimicrobial Agents and Chemotherapy.

Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare.

D. Nicolau, C. Nightingale, P. Tessier, 1995, The Journal of infectious diseases.

Comparison of 2 blood culture media shows significant differences in bacterial recovery for patients on antimicrobial therapy.

David N. Williams, M. Kuskowski, Christina A. Sutherland, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient

M. Bassetti, J. Pugin, D. Nicolau, 2016, Annals of Intensive Care.

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.

D. Nicolau, T. Edeki, Shampa Das, 2015, The Journal of antimicrobial chemotherapy.

Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients.

D. Nicolau, G. Leitz, C. Nightingale, 2003, Transplantation proceedings.

Amiodarone-cyclosporine interaction in a heart transplant patient.

C. Strange, D. Nicolau, W. Uber, 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Bactericidal Effect and Pharmacodynamics of Cethromycin (ABT-773) in a Murine Pneumococcal Pneumonia Model

D. Xuan, D. Nicolau, C. Nightingale, 2002, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic Assessment of Clarithromycin in a Murine Model of Pneumococcal Pneumonia

D. Xuan, D. Nicolau, C. Nightingale, 2002, Antimicrobial Agents and Chemotherapy.

Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen

D. Nicolau, R. Sabzwari, U. Patel, 2016, Infectious Diseases and Therapy.

Clinical Laboratory–Based Assay Methodologies May Underestimate and Increase Variability of Vancomycin Protein Binding in Hospitalized Patients

D. Nicolau, J. Crandon, S. MacVane, 2014, Pharmacotherapy.

Development of HPLC methods for the determination of vancomycin in human plasma, mouse serum and bronchoalveolar lavage fluid.

Christina A. Sutherland, D. Nicolau, Mao Hagihara, 2013, Journal of chromatographic science.

Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-Producing Enterobacterales in Animal Infection Models: a Current State of Affairs

D. Nicolau, Kamilia Abdelraouf, Tomefa E. Asempa, 2021, Antimicrobial Agents and Chemotherapy.

In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria.

D. Nicolau, Kamilia Abdelraouf, S. A. Almarzoky Abuhussain, 2020, The Journal of antimicrobial chemotherapy.

Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.

R. Wunderink, M. Niederman, B. Cao, 2019, The Lancet. Infectious diseases.

Inappropriate Antibiotic Use Due to Decreased Compliance with a Ventilator‐Associated Pneumonia Computerized Clinical Pathway: Implications for Continuing Education and Prospective Feedback

D. Nicolau, M. Nailor, J. Kuti, 2012, Pharmacotherapy.

Length of Stay and Hospital Costs Associated with a Pharmacodynamic‐Based Clinical Pathway for Empiric Antibiotic Choice for Ventilator‐Associated Pneumonia

D. Nicolau, J. Kuti, K. Eagye, 2010, Pharmacotherapy.

Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.

D. Nicolau, M. Monogue, J. Kuti, 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure

D. Nicolau, A. Thabit, J. Kuti, 2015, Antimicrobial Agents and Chemotherapy.

Vancomycin Tissue Pharmacokinetics in Patients with Lower-Limb Infections via In Vivo Microdialysis.

D. Nicolau, Ashley K. Shepard, A. A. Bhalodi, 2015, Journal of the American Podiatric Medical Association.

In Vitro Activity of Human-Simulated Epithelial Lining Fluid Exposures of Ceftaroline, Ceftriaxone, and Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus

D. Nicolau, S. MacVane, J. Kuti, 2014, Antimicrobial Agents and Chemotherapy.

Ceftriaxone, and Vancomycin against Methicillin-Susceptible and -Resistant 5

D. Nicolau, S. MacVane, J. Kuti, 2014 .

Comparative In Vivo Efficacies of Epithelial Lining Fluid Exposures of Tedizolid, Linezolid, and Vancomycin for Methicillin-Resistant Staphylococcus aureus in a Mouse Pneumonia Model

D. Nicolau, J. Crandon, P. Tessier, 2012, Antimicrobial Agents and Chemotherapy.

Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers

D. Nicolau, E. Salerno, J. Kuti, 2012, Antimicrobial Agents and Chemotherapy.

Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole

G. Drusano, G. Noel, D. Nicolau, 2009, Antimicrobial Agents and Chemotherapy.

Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.

L. Santos Filho, D. Nicolau, J. Kuti, 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation

D. Nicolau, J. Kuti, R. Pettit, 2019, Antimicrobial Agents and Chemotherapy.

Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?

D. Nicolau, M. Grupper, 2017, Current opinion in infectious diseases.

Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects

J. Shaw, D. Nicolau, C. Nightingale, 2006, Antimicrobial Agents and Chemotherapy.

Diagnostic and medical needs for therapeutic drug monitoring of antibiotics

A. van Belkum, D. Nicolau, J. Roberts, 2019, European Journal of Clinical Microbiology & Infectious Diseases.

Extended interval aminoglycoside dosing: from concept to clinic.

D. Nicolau, C. Nightingale, D. Maglio, 2002, International journal of antimicrobial agents.

Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department

D. Nicolau, K. Keyloun, M. Nailor, 2018, BMC Health Services Research.

Optimizing skin and skin structure infection outcomes: considerations of cost of care

D. Nicolau, M. Nailor, K. Goodlet, 2018, Expert review of pharmacoeconomics & outcomes research.

Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift

Y. Hamada, D. Nicolau, Jaime E Verastegui, 2016, Expert review of clinical pharmacology.

Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections.

D. Nicolau, S. Housman, Jami G Jain, 2014, The Journal of antimicrobial chemotherapy.

Efficacy of Human Simulated Exposures of Ceftaroline Administered at 600 Milligrams Every 12 Hours against Phenotypically Diverse Staphylococcus aureus Isolates

D. Nicolau, J. Crandon, R. Keel, 2011, Antimicrobial Agents and Chemotherapy.

Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models

D. Nicolau, Kamilia Abdelraouf, 2016, Antimicrobial Agents and Chemotherapy.

Cost Effect of Managing Methicillin‐Resistant Staphylococcus Aureus in a Long‐Term Care Facility

D. Nicolau, C. Nightingale, B. Capitano, 2003, Journal of the American Geriatrics Society.

Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model

R. Echols, D. Nicolau, M. Monogue, 2018, Antimicrobial Agents and Chemotherapy.

Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model

R. Echols, D. Nicolau, M. Monogue, 2018, Antimicrobial Agents and Chemotherapy.

Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa

D. Nicolau, M. Monogue, 2018, The Journal of antimicrobial chemotherapy.

Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis

D. Nicolau, R. Quintiliani, C. Nightingale, 1995, Antimicrobial agents and chemotherapy.

Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis

D. Nicolau, R. Quintiliani, C. Nightingale, 1993, Infection and immunity.

Influence of adjunctive ticlopidine on the treatment of experimental Staphylococcus aureus endocarditis.

D. Nicolau, R. Quintiliani, C. Nightingale, 1998, International journal of antimicrobial agents.

Making a Case for Pediatric Antimicrobial Stewardship Programs

D. Nicolau, Jennifer E. Girotto, N. Bennett, 2015, Pharmacotherapy.

Rifampin-Fluconazole Interaction in Critically ILL Patients

D. Nicolau, R. Quintiliani, C. Nightingale, 1995, The Annals of pharmacotherapy.

Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.

Christina A. Sutherland, D. Nicolau, Lindsay M. Avery, 2019, Journal of medical microbiology.

Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles

J. Quinn, D. Nicolau, K. Lolans, 2008, Infection and drug resistance.

Distribution of methicillin-resistant Staphylococcus aureus clones among health care facilities in Connecticut, New Jersey, and Pennsylvania. .

A. Tomasz, D. Nicolau, H. de Lencastre, 2000, Microbial drug resistance.

Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system

D. Nicolau, I. Ghazi, M. Grupper, 2017, Annals of Clinical Microbiology and Antimicrobials.

In vivo efficacy of humanized high dose meropenem and comparators against Pseudomonas aeruginosa isolates producing verona integron-encoded metallo-β-lactamase (VIM)

E. Lesho, P. McGann, D. Nicolau, 2016, Heliyon.

Prevalence of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut.

J. Quinn, D. Nicolau, C. Nightingale, 2004, Diagnostic microbiology and infectious disease.

In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth

D. Nicolau, J. Kuti, Maxwell J. Lasko, 2022, Antimicrobial agents and chemotherapy.

Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant Pseudomonas aeruginosa Using the ERACE-PA Global Surveillance Program

Y. Carmeli, L. Bourassa, H. Seifert, 2021, Open forum infectious diseases.

Assessment of sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Acinetobacter baumannii using in vitro chemostat and in vivo murine infection models

D. Nicolau, Kamilia Abdelraouf, Rio Nakamura, 2022, JAC-antimicrobial resistance.

Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization

Y. Carmeli, C. Burnham, L. Westblade, 2021, Antimicrobial agents and chemotherapy.

Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.

J. D. De Waele, M. Rizk, Elizabeth G. Rhee, 2021, International journal of antimicrobial agents.

In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine Lung Infection Model

D. Nicolau, Kamilia Abdelraouf, Maxwell J. Lasko, 2021, Antimicrobial Agents and Chemotherapy.

Evaluation of Metallo-β-Lactamase Susceptibility Testing in a Physiologic Medium

D. Nicolau, Tomefa E. Asempa, Hannah Bajor, 2021, Microbiology spectrum.

EDTA-modified carbapenem inactivation method (eCIM) for detecting IMP Metallo-β-lactamase–producing Pseudomonas aeruginosa: an assessment of increasing EDTA concentrations

D. Nicolau, Tomefa E. Asempa, Maxwell J. Lasko, 2020, BMC Microbiology.

Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology

D. Nicolau, Maxwell J. Lasko, 2020, Current Infectious Disease Reports.

Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms

D. Nicolau, J. Kuti, A. Kois, 2020, Current opinion in infectious diseases.

Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative

D. Nicolau, Tomefa E. Asempa, C. Gill, 2020, Antimicrobial Agents and Chemotherapy.

In Vivo Pharmacodynamic Profile of Ceftibuten-Clavulanate Combination against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in the Murine Thigh Infection Model

D. Nicolau, Kamilia Abdelraouf, S. Stainton, 2019, Antimicrobial Agents and Chemotherapy.

Single β-lactams versus combinations as empiric therapy for infections with Pseudomonas aeruginosa: assessing the in vitro susceptibility

Christina A. Sutherland, D. Nicolau, S. A. Almarzoky Abuhussain, 2020, Infectious diseases.

Efficacy of Humanized Cefiderocol Exposure Is Unaltered by Host Iron Overload in the Thigh Infection Model

D. Nicolau, Kamilia Abdelraouf, James M. Kidd, 2019, Antimicrobial Agents and Chemotherapy.

In vitro potency of antipseudomonal β-lactams against blood and respiratory isolates of P. aeruginosa collected from US hospitals.

Christina A. Sutherland, D. Nicolau, S. A. Almarzoky Abuhussain, 2019, Journal of thoracic disease.

Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model

D. Nicolau, R. Schuch, Kamilia Abdelraouf, 2019, Antimicrobial Agents and Chemotherapy.

In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model

K. Krause, D. Nicolau, Aryun Kim, 2018, Antimicrobial Agents and Chemotherapy.

Management of Pediatric Acute Hematogenous Osteomyelitis, Part I: Antimicrobial Stewardship Approach and Review of Therapies for Methicillin‐Susceptible Staphylococcus aureus, Streptococcus pyogenes, and Kingella kingae

D. Nicolau, Jennifer E. Girotto, Kailynn J DeRonde, 2018, Pharmacotherapy.

Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model

M. Pucci, D. Nicolau, T. Lister, 2018, Antimicrobial Agents and Chemotherapy.

Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints

D. Nicolau, Qi Wang, Hui Wang, 2018, Infection and drug resistance.

In Vitro Activity of Newer and Conventional Antimicrobial Agents, Including Fosfomycin and Colistin, against Selected Gram-Negative Bacilli in Kuwait

D. Nicolau, W. Alfouzan, R. Dhar, 2018, Pathogens.

Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model

D. Nicolau, Kamilia Abdelraouf, Lindsay M. Avery, 2018, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic Analysis of Daptomycin-Treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.

C. Arias, M. Weisser, D. Nicolau, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model

D. Nicolau, Kamilia Abdelraouf, S. A. Almarzoky Abuhussain, 2018, Antimicrobial Agents and Chemotherapy.

Management of Pediatric Acute Hematogenous Osteomyelitis, Part II: A Focus on Methicillin‐Resistant Staphylococcus aureus, Current and Emerging Therapies

D. Nicolau, Jennifer E. Girotto, Kailynn J DeRonde, 2018, Pharmacotherapy.

Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers

D. Nicolau, M. Monogue, Ashley K. Shepard, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains

D. Nicolau, M. Monogue, S. Stainton, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model

R. Bonomo, D. Nicolau, L. Abbo, 2017, Antimicrobial Agents and Chemotherapy.

Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model

R. Echols, D. Nicolau, M. Monogue, 2017, Antimicrobial Agents and Chemotherapy.

Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection

D. Nicolau, M. Monogue, 2017, Antimicrobial Agents and Chemotherapy.

Effects of Clinically Meaningful Concentrations of Antipseudomonal β-Lactams on Time to Detection and Organism Growth in Blood Culture Bottles

D. Nicolau, J. Kuti, J. Aslanzadeh, 2017, Journal of Clinical Microbiology.

Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds

Christina A. Sutherland, D. Nicolau, M. Grupper, 2017, Antimicrobial Agents and Chemotherapy.

Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory

D. Nicolau, J. Kuti, M. Grupper, 2016, Clinical Microbiology Reviews.

Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via In Vivo Microdialysis

D. Nicolau, M. Monogue, Ashley K. Shepard, 2017, Antimicrobial Agents and Chemotherapy.

Augmented Renal Clearance and How to Augment Antibiotic Dosing

D. Nicolau, I. Chen, 2020, Antibiotics.

Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.

D. Nicolau, S. Kotapati, C. Nightingale, 2005, The Journal of infection.

Pharmacokinetics of Cefazolin and Vancomycin in Infants Undergoing Open-Heart Surgery With Cardiopulmonary Bypass

Christina A. Sutherland, D. Nicolau, K. Gutierrez, 2019, Anesthesia and analgesia.

Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria

D. Nicolau, M. Nailor, Kristin E. Linder, 2016, Expert opinion on drug metabolism & toxicology.

Antibiotic stewardship challenges in the management of community-acquired infections for prevention of escalating antibiotic resistance.

M. Bassetti, D. Nicolau, J. Garau, 2014, Journal of global antimicrobial resistance.

Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection

Islam M. Ghazi, D. Nicolau, M. Nailor, 2016, Infection Control & Hospital Epidemiology.

Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model

C. Bissantz, D. Nicolau, Kamilia Abdelraouf, 2019, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients

D. Nicolau, C. Nightingale, Chonghua Li, 2006, Journal of clinical pharmacology.

Effect of Blood Product Resuscitation on the Pharmacokinetics of Ampicillin-Sulbactam during Orthotopic Liver Transplantation.

D. Nicolau, O. Serrano, J. Kuti, 2021, Surgical infections.

Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.

D. Nicolau, Kamilia Abdelraouf, Maxwell J. Lasko, 2021, The Journal of antimicrobial chemotherapy.

Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo-β-Lactamase-Producing Enterobacteriaceae

D. Nicolau, Tomefa E. Asempa, A. Bilinskaya, 2020, Journal of Clinical Microbiology.

The Ongoing Challenge with NDM-Harboring Enterobacteriaceae in Murine Infection Models

D. Nicolau, Kamilia Abdelraouf, Tomefa E. Asempa, 2020, Antimicrobial Agents and Chemotherapy.

1368. Assessment of the In Vivo Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination Against β-Lactamase-Producing Enterobacteriaceae in Neutropenic Lung Infection Model

C. Bissantz, D. Nicolau, Kamilia Abdelraouf, 2018, Open Forum Infectious Diseases.

Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model

D. Nicolau, J. Crandon, W. Nichols, 2013, Antimicrobial Agents and Chemotherapy.

Comparative Pharmacokinetics, Pharmacodynamics, and Tolerability of Ertapenem 1 Gram/Day Administered as a Rapid 5‐Minute Infusion versus the Standard 30‐Minute Infusion in Healthy Adult Volunteers

D. Nicolau, R. Quintiliani, D. Wiskirchen, 2013, Pharmacotherapy.

Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.

S. Braman, D. Nicolau, B. Capitano, 2004, Chest.

Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae.

D. Nicolau, J. Kuti, Heather K Sun, 2006, Chest.

Pharmacodynamic Target Attainment of Six β‐Lactams and Two Fluoroquinolones Against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella Species Collected from United States Intensive Care Units in 2004

D. Nicolau, J. Kuti, C. DeRyke, 2007, Pharmacotherapy.

START Stewardship Tactics for Antimicrobial Resistance Trends

T. File, D. Nicolau, K. Rodvold, 2009, Journal of Managed Care Pharmacy : JMCP.

Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae.

D. Nicolau, J. Kuti, P. Kontou, 2009, The American journal of emergency medicine.

Optimization of meropenem dosage in the critically ill population based on renal function

R. Ariano, D. Nicolau, J. Crandon, 2011, Intensive Care Medicine.

Time Required by Pharmacy Technicians to Reconstitute New versus Old Piperacillin/Tazobactam Formulations

D. Nicolau, J. Kuti, J. Sahni, 2007 .

Pharmacoeconomic Impact of Once‐Daily Aminoglycoside Administration

M. Klepser, D. Nicolau, R. Quintiliani, 1997, Pharmacotherapy.

Serum Piperacillin/Tazobactam Pharmacokinetics in a Morbidly Obese Individual

M. Postelnick, G. Noskin, D. Nicolau, 2007, The Annals of pharmacotherapy.

Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia.

D. Nicolau, J. Kuti, S. Housman, 2011, Clinics in chest medicine.

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia

D. Nicolau, A. Xiao, Jennifer A. Huntington, 2015, Journal of clinical pharmacology.

Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms

Y. Hamada, D. Nicolau, M. Monogue, 2016, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.

D. Nicolau, J. Chastre, A. Aubry, 2016, The Journal of antimicrobial chemotherapy.

Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus

D. Nicolau, J. Crandon, Wonhee So, 2016, Internal and Emergency Medicine.

In vitro microdialysis membrane efficiency of broad-spectrum antibiotics in combination and alone

D. Nicolau, S. MacVane, S. Housman, 2014, Clinical pharmacology : advances and applications.

Efficacy of Ceftaroline Fosamil in a Staphylococcal Murine Pneumonia Model

D. Nicolau, J. Crandon, D. Biek, 2012, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic approaches to optimizing beta-lactam therapy.

D. Nicolau, J. Crandon, 2011, Critical care clinics.

Current challenges in the management of the infected patient

D. Nicolau, 2011, Current opinion in infectious diseases.

In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms

Christina A. Sutherland, D. Nicolau, C. Bulik, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.

D. Nicolau, M. Palter, J. Kuti, 2010, Journal of critical care.

Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem

D. Nicolau, J. Kuti, Anthony M. Nicasio, 2009 .

Carbapenems: a potent class of antibiotics

D. Nicolau, 2008, Expert opinion on pharmacotherapy.

Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus Strains

D. Nicolau, P. Tessier, Somvadee Laohavaleeson, 2008, Antimicrobial Agents and Chemotherapy.

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.

D. Nicolau, R. Quintiliani, C. Nightingale, 2001, International journal of antimicrobial agents.

Comparison of clarithromycin and ciprofloxacin therapy for Bacillus anthracis Sterne infection in mice with or without (60)Co gamma-photon irradiation.

I. Brook, D. Nicolau, A. Germanà, 2005, Journal of medical microbiology.

Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery

D. Nicolau, J. Kuti, L. Maggio, 2017, Journal of clinical pharmacology.

Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococcus faecalis strains with various vancomycin susceptibilities.

D. Nicolau, C. Nightingale, C. Babalola, 2004, International journal of antimicrobial agents.

Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β-Lactam and Fluoroquinolone Concentrations

D. Nicolau, J. Kuti, I. Chen, 2019, Journal of Clinical Microbiology.

Influence of gentamicin dosing interval on the efficacy of penicillin-containing regimens in experimental Enterococcus faecalis endocarditis.

D. Nicolau, R. Quintiliani, C. Nightingale, 1997, The Journal of antimicrobial chemotherapy.

Simultaneous analysis of piperacillin and tazobactam in rabbits: application to pharmacokinetic study.

D. Xuan, D. Nicolau, C. Nightingale, 2005, Biomedical chromatography : BMC.

Isolation and quantitation of Clostridium difficile in aqueous and fecal matter using two types of selective media.

D. Nicolau, L. Lamb, M. Banevicius, 2016, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

Antibiotic kinetics and dynamics for the clinician.

D. Nicolau, R. Quintiliani, C. Nightingale, 1995, The Medical clinics of North America.

Pharmacodynamics of antimicrobials: treatment optimisation

D. Nicolau, J. Kuti, E. L. Gillespie, 2005, Expert opinion on drug metabolism & toxicology.

Critique of prevention of pneumococcal disease in high risk adults: A pharmacist‐based assessment of adult immunization protocols in clinical practice

D. Nicolau, J. Kuti, 2019, Journal of the American College of Clinical Pharmacy.

Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria

D. Nicolau, Lindsay M. Avery, 2018, Expert opinion on investigational drugs.

Cost‐Effectiveness of Ceftazidime by Continuous Infusion versus Intermittent Infusion for Nosocomial Pneumonia

D. Nicolau, R. Quintiliani, C. Nightingale, 2001, Pharmacotherapy.

Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis.

D. Nicolau, R. Shields, Derek N. Bremmer, 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria

D. Nicolau, Kamilia Abdelraouf, M. Nailor, 2017, Expert opinion on drug metabolism & toxicology.

Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.

D. Nicolau, C. Nightingale, Chonghua Li, 2007, Diagnostic microbiology and infectious disease.

Telavancin: a novel lipoglycopeptide for serious Gram-positive infections

D. Nicolau, J. Kuti, Somvadee Laohavaleeson, 2007, Expert opinion on investigational drugs.

In Vivo Efficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae Isolates

D. Nicolau, J. Crandon, S. MacVane, 2014, Antimicrobial Agents and Chemotherapy.

Lomefloxacin Clinical Pharmacokinetics

D. Nicolau, C. Nightingale, Collin D. Freeman, 1993, Clinical pharmacokinetics.

Pharmacoeconomics of Pneumocystis carinii Pneumonia in HIV-Infected and HIV-Noninfected Patients

D. Nicolau, R. Quintiliani, C. Nightingale, 1996, PharmacoEconomics.

Development of Neutropenic Murine Models of Iron Overload and Depletion To Study the Efficacy of Siderophore-Antibiotic Conjugates

D. Nicolau, Kamilia Abdelraouf, James M. Kidd, 2019, Antimicrobial Agents and Chemotherapy.

Differential Efficacy of Clarithromycin in Lung versus Thigh Infection Models

D. Nicolau, C. Nightingale, B. Capitano, 2004, Chemotherapy.

Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007)

D. Nicolau, Aryun Kim, J. Kuti, 2019, Infectious Diseases and Therapy.

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation

D. Nicolau, M. Monogue, M. Muhlebach, 2016, Antimicrobial Agents and Chemotherapy.

An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity.

M. Neely, D. Nicolau, M. Scheetz, 2016, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival

M. Neely, D. Nicolau, Jiajun Liu, 2015, Antimicrobial Agents and Chemotherapy.

Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections.

Y. Hamada, D. Nicolau, J. Kuti, 2015, The Journal of antimicrobial chemotherapy.

Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections ( cSSTI )

D. Nicolau, J. Kuti, Wonhee So, 2014 .

Management of community-acquired respiratory tract infections in an era of increasing antibiotic resistance

C. Asche, D. Nicolau, J. Sbarbaro, 2006 .

Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa

M. Klepser, D. Nicolau, R. Quintiliani, 1995, Antimicrobial agents and chemotherapy.

Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.

D. Nicolau, M. Dowzicky, J. Kuti, 2007, Clinical therapeutics.

Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling.

D. Nicolau, J. Kuti, K. Eagye, 2007, Surgical infections.

Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring.

D. Nicolau, R. Quintiliani, M. Chow, 1996, Therapeutic drug monitoring.

Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials

D. Nicolau, K. Lawrence, Tomefa E. Asempa, 2020, Open forum infectious diseases.

Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women.

D. Wing, D. Nicolau, J. McNulty, 2015, American journal of obstetrics and gynecology.

In Vitro Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii

D. Nicolau, J. Kuti, S. Housman, 2013, Antimicrobial Agents and Chemotherapy.

Risk Factors and Outcomes Associated with Isolation of Meropenem High-Level-Resistant Pseudomonas aeruginosa

D. Nicolau, J. Kuti, K. Eagye, 2009, Infection Control & Hospital Epidemiology.

Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.

D. Nicolau, Kamilia Abdelraouf, James M. Kidd, 2019, The Journal of antimicrobial chemotherapy.

The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey

M. Catani, Yonghong Xiao, P. Barie, 2017, World Journal of Emergency Surgery.

Containing Costs and Containing Bugs: Are They Mutually Exclusive?

D. Nicolau, 2009, Journal of managed care pharmacy : JMCP.

Antibacterial Effects of Moxifloxacin and Levofloxacin Simulating Epithelial Lining Fluid Concentrations gainst Community-Acquired Methicillin-Resistant

Christina A. Sutherland, D. Nicolau, S. Y. Lee, 2007, Drugs in R&D.

Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model.

D. Nicolau, S. Y. Lee, M. Banevicius, 2005, The Journal of antimicrobial chemotherapy.

Efficacy of Human Simulated Exposures of Ceftaroline against Phenotypically Diverse Enterobacteriaceae Isolates

D. Nicolau, J. Crandon, R. Keel, 2012, Antimicrobial Agents and Chemotherapy.

Efﬁcacy of Human Simulated Exposures of Ceftaroline Administered at 600 Milligrams Every 12 Hours against Phenotypically Diverse Staphylococcus aureus Isolates (cid:1)

D. Nicolau, J. Crandon, R. Keel, 2011 .

Pharmacodynamics of Tigecycline against Phenotypically Diverse Staphylococcus aureus Isolates in a Murine Thigh Model

D. Nicolau, J. Crandon, M. Banevicius, 2008, Antimicrobial Agents and Chemotherapy.

Beneficial Effect of Adjunctive Azithromycin in Treatment of Mucoid Pseudomonas aeruginosa Pneumonia in the Murine Model

D. Nicolau, R. Quintiliani, C. Nightingale, 1999, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic Profile of Tigecycline against Methicillin-Resistant Staphylococcus aureus in an Experimental Pneumonia Model

D. Nicolau, Li Peng, J. Crandon, 2009, Antimicrobial Agents and Chemotherapy.

Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects

R. Echols, D. Nicolau, T. Wajima, 2021, Journal of clinical pharmacology.

Comparative efficacy of human-simulated epithelial lining fluid exposures of tedizolid, linezolid and vancomycin in neutropenic and immunocompetent murine models of staphylococcal pneumonia

D. Nicolau, Kamilia Abdelraouf, James M. Kidd, 2018, The Journal of antimicrobial chemotherapy.

Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.

R. Baughman, Christina A. Sutherland, D. Nicolau, 2012, Pulmonary pharmacology & therapeutics.

Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults

D. Nicolau, P. Crownover, J. Crandon, 2009, Antimicrobial Agents and Chemotherapy.

Intrapulmonary Concentrations of Telithromycin: Clinical Implications for Respiratory Tract Infections due to Streptococcus pneumoniae

D. Nicolau, C. Nightingale, P. K. Dandekar, 2005, Chemotherapy.

Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts.

D. Nicolau, S. Kotapati, C. Nightingale, 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts.

D. Nicolau, C. Nightingale, J. Kuti, 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations.

L. Saiman, D. Nicolau, N. Neu, 2018, Diagnostic microbiology and infectious disease.

Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae

D. Nicolau, C. Nightingale, N. R. Florea, 2004, Antimicrobial Agents and Chemotherapy.

Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections

D. Nicolau, R. Quintiliani, C. Nightingale, 1996, Antimicrobial agents and chemotherapy.

Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides.

D. Nicolau, C. Nightingale, D. Maglio, 2003, Infectious disease clinics of North America.

Evaluation of telithromycin against Streptococcus pneumoniae with ribosomal mutations utilizing in vitro time-kill methodology.

D. Farrell, D. Nicolau, C. Nightingale, 2005, International journal of antimicrobial agents.

Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model.

D. Farrell, D. Nicolau, C. Nightingale, 2005, International journal of antimicrobial agents.

Circulating Tumor Necrosis Factor-Alpha Production during the Progression of Rat Endotoxic Sepsis

D. Xuan, D. Nicolau, R. Quintiliani, 2001, Chemotherapy.

Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid

D. Nicolau, R. Quintiliani, C. Nightingale, 1994, Antimicrobial Agents and Chemotherapy.

An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes

D. Nicolau, A. Thabit, 2016, Infection and drug resistance.

Humanized Exposures of a β-Lactam-β-Lactamase Inhibitor, Tazobactam, versus Non-β-Lactam-β-Lactamase Inhibitor, Avibactam, with or without Colistin, against Acinetobacter baumannii in Murine Thigh and Lung Infection Models

V. Nizet, D. Nicolau, M. Monogue, 2018, Pharmacology.

Effect of adjunctive treatment with gamma interferon against Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.

D. Nicolau, C. Nightingale, C. Babalola, 2004, International journal of antimicrobial agents.

A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin

K. Garey, D. Nicolau, M. Khaleduzzaman, 2016, Annals of Clinical Microbiology and Antimicrobials.

Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function

D. Nicolau, A. Thabit, J. Kuti, 2017, Journal of pharmacy practice.

Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection

K. Itani, D. Mercer, D. Nicolau, 2006, Antimicrobial Agents and Chemotherapy.

Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline

D. Nicolau, 2009, Expert opinion on pharmacotherapy.

In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing Pseudomonas aeruginosa strains.

D. Nicolau, A. Gales, R. Cayô, 2021, Diagnostic microbiology and infectious disease.

Evaluation of the EDTA-Modified Carbapenem Inactivation Method for Detecting Metallo-β-Lactamase-Producing Pseudomonas aeruginosa

D. Nicolau, Tomefa E. Asempa, Maxwell J. Lasko, 2020, Journal of Clinical Microbiology.

Carbapenem Non-susceptible Pseudomonas aeruginosa from Intensive Care Units in the United States: A Potential Role for New β-lactam Combination Agents

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2019 .

In Vitro Activity of Novel Gyrase Inhibitors against a Highly Resistant Population of Pseudomonas aeruginosa

D. Nicolau, P. Tessier, 2013, Antimicrobial Agents and Chemotherapy.

Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens.

E. Goldstein, G. Stein, D. Nicolau, 2008, Anaerobe.

Pharmacodynamic Profile of Ertapenem against Klebsiella pneumoniae and Escherichia coli in a Murine Thigh Model

Christina A. Sutherland, D. Nicolau, C. Nightingale, 2005, Antimicrobial Agents and Chemotherapy.

The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa

Y. Carmeli, C. Burnham, L. Bourassa, 2021, European Journal of Clinical Microbiology & Infectious Diseases.

Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.

C. Gomersall, D. Nicolau, J. Roberts, 2011, International journal of antimicrobial agents.

Changes in Pharmacodynamic Target Attainment for Antimicrobials Over a 2-Year Period: Results of the 2004 OPTAMA Program in North America

D. Nicolau, J. Kuti, C. DeRyke, 2007 .

Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model.

D. Nicolau, R. Quintiliani, C. Nightingale, 1999, The Journal of antimicrobial chemotherapy.

Pharmacokinetic Profile of Meropenem, Administered at 500 Milligrams Every 8 Hours, in Plasma and Cantharidin-Induced Skin Blister Fluid

D. Nicolau, C. Nightingale, R. Teng, 2003, Antimicrobial Agents and Chemotherapy.

Stability of meropenem in polyvinyl chloride bags and an elastomeric infusion device.

D. Nicolau, S. Bauer, D. L. Smith, 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

In vitro reduction of endotoxin concentrations with the 5S fragment of immunoglobulin G

D. Xuan, D. Nicolau, R. Quintiliani, 1997, Antimicrobial agents and chemotherapy.

Pharmacokinetics of Intravenous Linezolid in Moderately to Morbidly Obese Adults

D. Nicolau, P. Papasavas, J. Kuti, 2012, Antimicrobial Agents and Chemotherapy.

Serum Bactericidal Activities of High-Dose Daptomycin with and without Coadministration of Gentamicin against Isolates of Staphylococcus aureus and Enterococcus species

Bo Zhang, Christina A. Sutherland, D. Nicolau, 2006, Antimicrobial Agents and Chemotherapy.

Meropenem Administered as a Prolonged Infusion to Treat Serious Gram‐Negative Central Nervous System Infections

D. Paterson, D. Nicolau, R. Venkataramanan, 2004, Pharmacotherapy.

Clinical Efficacy and Pharmacoeconomics of a Continuous‐Infusion Piperacillin‐Tazobactam Program in a Large Community Teaching Hospital

D. Nicolau, R. Quintiliani, C. Nightingale, 2002, Pharmacotherapy.

Cefepime Dosing in the Morbidly Obese Patient Population

P. Barie, A. Pomp, V. Ho, 2012, Obesity Surgery.

Review of antimicrobial use and considerations in the elderly population

D. Nicolau, Samantha Green, A. Giarratano, 2018, Clinical interventions in aging.

Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration

D. Nicolau, S. Nouér, T. M. Da Costa, 2019, BMC Infectious Diseases.

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis

D. van Duin, D. Nicolau, A. Thabit, 2016, Antimicrobial Agents and Chemotherapy.

Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.

D. Nicolau, J. Kuti, C. DeRyke, 2007, Diagnostic microbiology and infectious disease.

Empiric Pharmacodynamic Performance of 9 Antimicrobials Against Pathogens Implicated in the Cause of Complicated Skin and Soft Tissue Infections: A Report From the OPTAMA Program

D. Nicolau, S. Y. Lee, J. Kuti, 2006 .

Evolving epidemiology and cost of resistance to antimicrobial agents in long-term care facilities.

D. Nicolau, B. Capitano, 2003, Journal of the American Medical Directors Association.

Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient

V. Waters, D. Nicolau, J. Zuckerman, 2015, Antimicrobial Agents and Chemotherapy.

Klebsiella pneumoniae by Various Testing Methods 5

S. Jenkins, D. Nicolau, J. Vincent, 2010 .

Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for other Enterococcal species by the Clinical and Laboratory Standards Institute.

M. Weinstein, R. Humphries, J. Jorgensen, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium.

M. Lorenzo, S. Jenkins, D. Nicolau, 2019, The Journal of antimicrobial chemotherapy.

Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model

R. Humphries, D. Nicolau, Kamilia Abdelraouf, 2018, Antimicrobial Agents and Chemotherapy.

Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus

D. Nicolau, R. Quintiliani, C. Nightingale, 1994, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetics of Continuous Infusion Ceftazidime

D. Nicolau, B. Frame, Bryan Facca, 1999, Clinical pharmacokinetics.

Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin

D. Nicolau, 2004, Expert opinion on pharmacotherapy.

Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.

D. Nicolau, Aryun Kim, P. Koomanachai, 2008, The Journal of antimicrobial chemotherapy.

Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients.

D. Nicolau, R. Quintiliani, C. Nightingale, 1995, The Journal of antimicrobial chemotherapy.

Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae

D. Nicolau, J. Kuti, S. A. Almarzoky Abuhussain, 2018, Antimicrobial Agents and Chemotherapy.

Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection.

D. Nicolau, C. Nightingale, C. Onyeji, 2000, The Journal of antimicrobial chemotherapy.

Treatment of Clostridium difficile Infection With Tigecycline: Proof of Concept Study

E. Goldstein, G. Stein, V. Young, 2013 .

PHARMACODYNAMIC CONSIDERATIONS IN ORAL CEPHALOSPORIN THERAPY-. IMPLICATIONS FOR SELECTION AND EFFECTIVENESS

D. Nicolau, 1998 .

Choosing between the New Cephalosporin Antibiotics

D. Nicolau, R. Quintiliani, 2012, PharmacoEconomics.

Cephalosporin-metronidazole combinations in the management of intra-abdominal infections.

D. Nicolau, R. Quintiliani, C. Nightingale, 1995, Diagnostic microbiology and infectious disease.

Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices.

D. Nicolau, J. Kuti, I. Chen, 2020, Clinical therapeutics.

Pharmacokinetic and pharmacodynamic properties of meropenem.

D. Nicolau, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections

D. Nicolau, Chonghua Li, J. Kuti, 2007, Antimicrobial Agents and Chemotherapy.

Chapter 8 – Rationale and utility of therapeutic drug monitoring for the optimization of antibiotic therapy

D. Nicolau, C. Ong, 2004 .

A guide to therapeutic drug monitoring of β‐lactam antibiotics

D. Nicolau, J. Kuti, A. Fratoni, 2021, Pharmacotherapy.

Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration

D. Nicolau, K. Singaravelu, Emir Kobic, 2022, Open forum infectious diseases.

The use of continuous infusion ceftolozane/tazobactam for resistant gram-negative bacterial infections: a retrospective analysis and brief review of the literature.

D. Nicolau, P. Bookstaver, J. Justo, 2020, International journal of antimicrobial agents.

In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa.

D. Nicolau, A. Gales, R. Cayô, 2020, The Journal of antimicrobial chemotherapy.

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections

D. Nicolau, M. Nailor, K. Goodlet, 2016, Therapeutics and clinical risk management.

Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.

P. Kiratisin, D. Nicolau, R. Keel, 2013, International journal of antimicrobial agents.

Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen.

D. Xuan, D. Nicolau, C. Nightingale, 2000, International journal of antimicrobial agents.

The pharmacodynamics of aminoglycosides.

D. Nicolau, R. Quintiliani, C. Nightingale, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Optimizing Antibiotic Administration for Pneumonia.

D. Nicolau, James M. Kidd, Ana Motos, 2018, Clinics in chest medicine.

Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria

D. Nicolau, J. Kuti, James M. Kidd, 2018, Expert opinion on pharmacotherapy.

Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.

D. Nicolau, Aryun Kim, J. Kuti, 2009, Clinical therapeutics.

Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs.

D. Nicolau, Aryun Kim, J. Crandon, 2009, The Journal of antimicrobial chemotherapy.

Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients

D. Nicolau, C. Gill, 2022, Antimicrobial Resistance & Infection Control.

Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance.

D. Nicolau, J. Kuti, John W. Mah, 2022, The Journal of antimicrobial chemotherapy.

Pharmacodynamics of Intermittent- and Continuous-Infusion Cefepime Alone and in Combination with Once-Daily Tobramycin against Pseudomonas aeruginosa in an in vitro Infection Model

D. Nicolau, C. Nightingale, P. Tessier, 1999, Chemotherapy.

Use of Daptomycin for the Treatment of Methicillin-Resistant Coagulase-Negative Staphylococcal Ventriculitis

D. Rubin, D. Nicolau, C. Urban, 2012, Case reports in medicine.

Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.

Y. Carmeli, E. Goldstein, D. Nicolau, 2012, International journal of antimicrobial agents.

Comparative Efﬁcacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model (cid:1)

D. Nicolau, J. Crandon, J. Kuti, 2010 .

Evaluation of high-concentration EDTA-modified carbapenemase inactivation method (eCIM) for SPM-producing Pseudomonas aeruginosa

D. Nicolau, C. Kiffer, Maxwell J. Lasko, 2021, Archives of Microbiology.

Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance

T. Walsh, D. Nicolau, A. Michel, 2019, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.

Islam M. Ghazi, D. Nicolau, M. Monogue, 2017, International journal of antimicrobial agents.

Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States

D. Nicolau, Aryun Kim, J. Kuti, 2011, Mycoses.

Bronchopulmonary Disposition of Micafungin in Healthy Adult Volunteers

D. Nicolau, J. Kuti, P. Tessier, 2008, Antimicrobial Agents and Chemotherapy.

Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa

Islam M. Ghazi, D. Nicolau, M. Monogue, 2018, Pharmacology.

Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis – A review of 3 cases

D. Nicolau, R. Quintiliani, J. Kuti, 2010 .

Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model

D. Nicolau, J. Crandon, Wonhee So, 2015, Antimicrobial Agents and Chemotherapy.

Managementofcomplicated infectionsintheeraof antimicrobialresistance:therole oftigecycline

D. Nicolau, 2009 .

In Vivo Efficacy of Human Simulated Regimens of Carbapenems and Comparator Agents against NDM-1-Producing Enterobacteriaceae

P. Nordmann, D. Nicolau, D. Wiskirchen, 2013, Antimicrobial Agents and Chemotherapy.

Inhaled antimicrobial therapies for respiratory infections

D. Nicolau, S. Kim, J. Kuti, 2008, Current infectious disease reports.

Clearance of Quinupristin-Dalfopristin (Synercid®) and their main Metabolites during Continuous Veno-Venous Hemofiltration (CVVH) with or without Dialysis

M. Zhong, D. Nicolau, C. Nightingale, 2002, The International journal of artificial organs.

Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2019, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae

D. Nicolau, J. Crandon, 2015, Pathogens.

Use of a bioabsorbable polymer for the delivery of ofloxacin during experimental osteomyelitis treatment

B. Browner, D. Nicolau, C. Nightingale, 1998, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

Comparative Efficacies of Human Simulated Exposures of Tedizolid and Linezolid against Staphylococcus aureus in the Murine Thigh Infection Model

D. Nicolau, J. Crandon, P. Tessier, 2012, Antimicrobial Agents and Chemotherapy.

Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.

R. Owens, D. Nicolau, R. Quintiliani, 1999, International journal of antimicrobial agents.

Efficacy of Humanized High-Dose Meropenem, Cefepime, and Levofloxacin against Enterobacteriaceae Isolates Producing Verona Integron-Encoded Metallo-β-Lactamase (VIM) in a Murine Thigh Infection Model

Islam M. Ghazi, E. Lesho, P. McGann, 2015, Antimicrobial Agents and Chemotherapy.

Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.

L. Saiman, D. Nicolau, N. Neu, 2016, The Journal of antimicrobial chemotherapy.

Intrapulmonary Pharmacokinetics of high doses of tigecycline in patients with Ventilator-Associated Pneumonia (VAP)

A. Dokoumetzidis, D. Nicolau, G. Dimopoulos, 2021, International Journal of Antimicrobial Agents.

Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa

D. Nicolau, J. Crandon, J. Kuti, 2009, Antimicrobial Agents and Chemotherapy.

Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.

D. Nicolau, S. Y. Lee, J. Kuti, 2007, Journal of Infection.

Subcutaneous cefazolin to reduce surgical site infections in a porcine model.

Joshua D. Rouch, John P. Koulakis, S. Putterman, 2018, The Journal of surgical research.

Prophylaxis of Acute Osteomyelitis with Absorbable Ofloxacin-Impregnated Beads

D. Nicolau, C. Nightingale, H. Kourea, 1998, Antimicrobial Agents and Chemotherapy.

Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis

M. Klepser, D. Nicolau, R. Quintiliani, 1997, Antimicrobial agents and chemotherapy.

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.

D. Nicolau, J. Crandon, Jared L. Crandon, 2008, Future microbiology.

Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.

P. Charifson, L. Swenson, T. Grossman, 2008, Journal of medicinal chemistry.

Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion

J. Bosso, D. Nicolau, K. Perez, 2016, Hospital practice.

Review of dalbavancin, a novel semisynthetic lipoglycopeptide

D. Nicolau, Aryun Kim, J. Kuti, 2007, Expert opinion on investigational drugs.

Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose

J. Loutit, D. Nicolau, S. Porter, 2005, Antimicrobial Agents and Chemotherapy.

Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV.

P. Charifson, D. Nicolau, B. Hanzelka, 2015, ACS medicinal chemistry letters.

Determination of the In Vivo Pharmacodynamic Profile of Cefepime against Extended-Spectrum-Beta-Lactamase-Producing Escherichia coli at Various Inocula

D. Nicolau, C. Nightingale, M. Banevicius, 2004, Antimicrobial Agents and Chemotherapy.

Effect of Continuous Arteriovenous Hemodiafiltration on the Pharmacokinetics of Fluconazole

D. Nicolau, R. Quintiliani, C. Nightingale, 1994, Pharmacotherapy.

Pharmacodynamics of Macrolides, Azalides, and Ketolides

D. Nicolau, Wonhee So, 2016 .

Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis

P. Courvalin, D. Nicolau, R. Quintiliani, 1996, Antimicrobial agents and chemotherapy.

In Vitro Pharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureus

D. Nicolau, D. Wiskirchen, J. Kuti, 2011, Antimicrobial Agents and Chemotherapy.

Bactericidal Activity of Low‐Dose Ceftizoxime Plus Metronidazole Compared With Cefoxitin and Ampicillin‐Sulbactam

D. Xuan, D. Nicolau, R. Quintiliani, 1994, Pharmacotherapy.

In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates

R. Owens, D. Nicolau, R. Quintiliani, 1997, Antimicrobial agents and chemotherapy.

Treatment of Multidrug‐Resistant Pseudomonas aeruginosa Using Extended‐Infusion Antimicrobial Regimens

K. Thom, D. Nicolau, E. Heil, 2015, Pharmacotherapy.

Clinical Pharmacokinetics of Newer Cephalosporins

Michael E. Klepser, M. Klepser, D. Nicolau, 1995, Clinical pharmacokinetics.

Determination of the Pharmacodynamic Profile of Daptomycin against Streptococcus pneumoniae Isolates with Varying Susceptibility to Penicillin in a Murine Thigh Infection Model

P. Williams, D. Nicolau, C. Nightingale, 2004, Chemotherapy.

A Novel Dosing Strategy of Ceftolozane/Tazobactam in a Patient Receiving Intermittent Hemodialysis

D. Nicolau, Dayna McManus, J. Topal, 2021, Open forum infectious diseases.

Pharmacoeconomic Analysis of Amphotericin B Lipid Complex versus Liposomal Amphotericin B in the Treatment of Fungal Infections

P. Williams, D. Nicolau, S. Kotapati, 2012, PharmacoEconomics.

Tissue Pharmacokinetics of Cefazolin in Patients with Lower Limb Infections

D. Nicolau, Ashley K. Shepard, A. A. Bhalodi, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.

Christina A. Sutherland, D. Nicolau, S. Housman, 2014, International journal of antimicrobial agents.

Thalidomide: Treatment of Severe Recurrent Aphthous Stomatitis in Patients with Aids

T. West, D. Nicolau, T. West, 1990, DICP : the annals of pharmacotherapy.

Multi-center evaluation of antifungal time-kill methods

M. Klepser, M. Pfaller, D. Nicolau, 2001 .

Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci.

D. Nicolau, R. Quintiliani, C. Nightingale, 2000, International journal of antimicrobial agents.

Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.

S. Jenkins, B. Kreiswirth, D. Nicolau, 2020, International journal of antimicrobial agents.

Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.

D. Nicolau, S. Y. Lee, J. Kuti, 2005, Surgical infections.

Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.

Y. Hamada, D. Nicolau, J. Crandon, 2016, The Journal of antimicrobial chemotherapy.

In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.

D. Nicolau, Kamilia Abdelraouf, C. Gill, 2021, The Journal of antimicrobial chemotherapy.

In Vivo Pharmacodynamic Profiling of Doripenem against Pseudomonas aeruginosa by Simulating Human Exposures

D. Nicolau, Aryun Kim, M. Banevicius, 2008, Antimicrobial Agents and Chemotherapy.

Influence of piperacillin-tazobactam on pharmacokinetics of gentamicin given once daily.

D. Nicolau, C. Nightingale, K. B. Patel, 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002

D. Nicolau, C. Nightingale, J. Kuti, 2004, Antimicrobial Agents and Chemotherapy.

Performance of the PIRO Score for Predicting Mortality in Patients with Ventilator-Associated Pneumonia

D. Nicolau, D. Wiskirchen, G. Furtado, 2012, Anaesthesia and intensive care.

Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles.

D. Nicolau, David P. Nicolau, 2001, Infection.

Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Pseudomonas aeruginosa Meningitis

Carolyn Fernandes, D. Nicolau, R. Shields, 2020, Open forum infectious diseases.

Precision medicine for the diagnosis and treatment of carbapenem-resistant Enterobacterales: time to think from a different perspective

D. Nicolau, Sergio Reyes, 2020, Expert review of anti-infective therapy.

Management of KPC-producing Klebsiella pneumoniae infections.

M. Bassetti, E. Righi, C. Viscoli, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Meropenem-Nacubactam Activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a Neutropenic Murine Lung Infection Model.

C. Bissantz, D. Nicolau, Kamilia Abdelraouf, 2019, International journal of antimicrobial agents.

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)

M. Boermeester, Yonghong Xiao, Soumitra R. Eachempati, 2016, World Journal of Emergency Surgery.

Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.

D. Nicolau, C. Nightingale, P. Tessier, 2003, The Journal of antimicrobial chemotherapy.

Oral Bioavailability and Pharmacokinetics of Trovafloxacin in Patients with AIDS

D. Nicolau, R. Quintiliani, C. Nightingale, 1999, Antimicrobial Agents and Chemotherapy.

Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS

R. Owens, D. Nicolau, R. Quintiliani, 1997, Antimicrobial agents and chemotherapy.

Population pharmacokinetic analysis of the microemulsion formulation of cyclosporin A (Neoral®) in renal transplant patients

D. Xuan, D. Nicolau, C. Nightingale, 2006 .

Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model.

D. Nicolau, R. Schuch, D. Lehoux, 2021, The Journal of antimicrobial chemotherapy.

Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.

D. Nicolau, J. Kuti, J. Ellis, 2005, Clinical therapeutics.

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients

C H Nightingale, D. Nicolau, R. Quintiliani, 1995, Antimicrobial agents and chemotherapy.

Pharmacokinetic Profile of Tigecycline in Serum and Skin Blister Fluid of Healthy Subjects after Multiple Intravenous Administrations

S. Troy, D. Nicolau, C. Nightingale, 2005, Antimicrobial Agents and Chemotherapy.

Streptococcus pneumoniae Response to Repeated Moxifloxacin or Levofloxacin Exposure in a Rabbit Tissue Cage Model

D. Xuan, M. Zhong, D. Nicolau, 2001, Antimicrobial Agents and Chemotherapy.

Disposition of ofloxacin in female New Zealand white rabbits.

M. Klepser, D. Nicolau, C. Nightingale, 1997, Journal of veterinary pharmacology and therapeutics.

Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target?

D. Nicolau, M. Monogue, 2019, Expert review of anti-infective therapy.

In Vivo Activities of Simulated Human Doses of Cefepime and Cefepime-AAI101 against Multidrug-Resistant Gram-Negative Enterobacteriaceae

D. Nicolau, J. Crandon, 2015, Antimicrobial Agents and Chemotherapy.

A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2019, Clinical therapeutics.

Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis.

D. Nicolau, R. Gutierrez, Wesley D. Kufel, 2022, The Journal of antimicrobial chemotherapy.

In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.

D. Nicolau, J. Kuti, S. Housman, 2013, The Journal of antimicrobial chemotherapy.

In Vitro Pharmacodynamics of Simulated Pulmonary Exposures of Tigecycline Alone and in Combination against Klebsiella pneumoniae Isolates Producing a KPC Carbapenemase

D. Nicolau, D. Wiskirchen, J. Kuti, 2011, Antimicrobial Agents and Chemotherapy.

In Vivo Pharmacodynamic Profile of Tigecycline against Phenotypically Diverse Escherichia coli and Klebsiella pneumoniae Isolates

D. Nicolau, J. Crandon, Anthony M. Nicasio, 2009, Antimicrobial Agents and Chemotherapy.

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

D. Nicolau, Joseph L Kuti, Charles H Nightingale, 2003, Journal of clinical pharmacology.

Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii

D. Nicolau, I. Ghazi, M. Grupper, 2017, Infectious diseases.

Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae

D. Nicolau, C. Bulik, 2011, Antimicrobial Agents and Chemotherapy.

Minor fluctuations in renal function may alter therapeutic drug concentrations substantially during high-dose, continuous-infusion beta-lactam therapy for multi-drug-resistant Gram-negative bacilli.

P. Barie, V. Ho, C. Afaneh, 2012, Surgical infections.

The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms

D. Nicolau, J. Crandon, M. Hagihara, 2012, Expert opinion on drug safety.

Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics

D. Nicolau, M. Nailor, M. Zmarlicka, 2015, Infection and drug resistance.

Intra-abdominal infections: considerations for the use of the carbapenems

D. Nicolau, I. Kioumis, J. Kuti, 2007, Expert opinion on pharmacotherapy.

Comparison of Pharmacodynamic Target Attainment Between Healthy Subjects and Patients for Ceftazidime and Meropenem

D. Nicolau, Joseph L Kuti, Sheryl Horowitz, 2005, Pharmacotherapy.

Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae.

D. Nicolau, J. Crandon, Wonhee So, 2015, The Journal of urology.

Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics.

G. Stein, D. Nicolau, 2010, Journal of the American Podiatric Medical Association.

Overview perspective of bacterial resistance

D. Nicolau, G. Furtado, 2010, Expert opinion on therapeutic patents.

Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa

M. Klepser, D. Nicolau, R. Quintiliani, 1997, Antimicrobial agents and chemotherapy.

Pharmacokinetic/Pharmacodynamic Optimization of Hospital-Acquired and Ventilator-Associated Pneumonia: Challenges and Strategies.

D. Nicolau, Y. Abouelhassan, 2022, Seminars in respiratory and critical care medicine.

Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation.

D. Nicolau, J. Kuti, Shawn H. MacVane, 2014, International journal of antimicrobial agents.

Optimising Dosing Strategies of Antibacterials Utilising Pharmacodynamic Principles

Su Young Lee, D. Nicolau, S. Y. Lee, 2012, Drugs.

Optimizing bactericidal exposure for β‐lactams using prolonged and continuous infusions in the pediatric population

Joshua D. Courter, D. Nicolau, Jennifer E. Girotto, 2009, Pediatric blood & cancer.

Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia

R. Ariano, D. Nicolau, Aryun Kim, 2009, Antimicrobial Agents and Chemotherapy.

Employing pharmacokinetic and pharmacodynamic principles to optimize antimicrobial treatment in the face of emerging resistance

D. Nicolau, J. Kuti, L. S. Filho, 2007 .

A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit.

D. Nicolau, C. Mendes, C. Kiffer, 2007, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

PHARMACOKINETICS OF CONTINUOUS AND INTERMITTENT CEFTAZIDIME IN INTENSIVE CARE UNIT PATIENTS WITH NOSOCOMIAL PNEUMONIA

D. Nicolau, R. Quintiliani, C. Nightingale, 1999 .

Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients

K. Thom, D. Nicolau, J. Roberts, 2018, Antimicrobial Agents and Chemotherapy.

Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.

D. Nicolau, J. Kuti, A. Dana, 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Optimizing Antibiotic-Related Outcomes in the Critically Ill Patient

D. Nicolau, J. Kuti, 2005 .

Pharmacokinetic and Pharmacodynamic Evaluation of Two Dosing Regimens for Piperacillin‐Tazobactam

D. Xuan, D. Nicolau, R. Quintiliani, 2002, Pharmacotherapy.

A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid-liquid extraction and reversed-phase HPLC.

D. Nicolau, C. Nightingale, Chonghua Li, 2005, Journal of pharmaceutical and biomedical analysis.

Pharmacodynamic Profile of Telithromycin against Macrolide- and Fluoroquinolone-Resistant Streptococcus pneumoniae in a Neutropenic Mouse Thigh Model

D. Nicolau, C. Nightingale, Holly M. Mattoes, 2005, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2019, Antimicrobial Agents and Chemotherapy.

Update on daptomycin: the first approved lipopeptide antibiotic

D. Nicolau, S. Y. Lee, J. Kuti, 2006, Expert opinion on pharmacotherapy.

Streamlining antimicrobial therapy for lower respiratory tract infections.

D. Nicolau, R. Quintiliani, C. Nightingale, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics of Intravenous and Oral Linezolid in Adults with Cystic Fibrosis

C. Kloft, D. Nicolau, M. Muhlebach, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic Target Attainment of Oral β-Lactams for the Empiric Treatment of Acute Otitis Media in Children

G. Doern, D. Nicolau, Jennifer E. Girotto, 2008, Paediatric drugs.

Probability of Achieving Requisite Pharmacodynamic Exposure for Oral β-Lactam Regimens against Haemophilus influenzae in Children

M. Pichichero, G. Doern, D. Nicolau, 2008, Paediatric drugs.

Stability of doripenem in polyvinyl chloride bags and elastomeric pumps.

Christina A. Sutherland, D. Nicolau, J. Crandon, 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A Retrospective Case Series of Concomitant Carbapenem and Valproic Acid Use: Are Best Practice Advisories Working?

D. Nicolau, J. Kuti, Kristin E. Linder, 2021, Journal of pharmacy practice.

Cost-Effective Approaches to the Treatment of Community-Acquired Pneumonia in the Era of Resistance

D. Nicolau, B. Capitano, J. Kuti, 2012, PharmacoEconomics.

Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model

D. Nicolau, H. Fan, M. Banevicius, 2007, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetics and Pharmacodynamics of Meropenem in Pediatric Patients

D. Nicolau, C. Nightingale, Chonghua Li, 2006, Journal of clinical pharmacology.

Role of pharmacodynamics in designing dosage regimens for beta-lactams.

D. Nicolau, S. Kotapati, C. Nightingale, 2003, Connecticut medicine.

Pharmacokinetics of High-Dose Meropenem in Adult Cystic Fibrosis Patients

D. Nicolau, P. Ambrose, R. Quintiliani, 2001, Chemotherapy.

Carbapenemase-producing Pseudomonas aeruginosa –an emerging challenge

F. Tenover, D. Nicolau, C. Gill, 2022, Emerging microbes & infections.

Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.

D. Nicolau, C. Mendes, C. Kiffer, 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

In Vitro Pharmacodynamics of Human Simulated Exposures of Ceftaroline and Daptomycin against MRSA, hVISA, and VISA with and without Prior Vancomycin Exposure

D. Nicolau, J. Kuti, A. A. Bhalodi, 2013, Antimicrobial Agents and Chemotherapy.

Newer developments in the treatment of Gram-positive infections

D. Nicolau, J. Crandon, P. Koomanachai, 2009, Expert opinion on pharmacotherapy.

Prevalence of Methicillin-Resistant Staphylococcus aureus Strains With Vancomycin Minimum Inhibitory Concentration 2 &mgr;g/mL in New York City Area Hospitals and Implications on Pharmacodynamic Target Attainment

D. Nicolau, Aryun Kim, G. Sakoulas, 2009 .

A Pharmacodynamic Simulation to Assess Tigecycline Efficacy for Hospital-Acquired Pneumonia Compared with Other Common Intravenous Antibiotics

D. Nicolau, M. Dowzicky, J. Kuti, 2008, Journal of chemotherapy.

Influence of adjunct azithromycin on the mortality of experimental Pseudomonas aeruginosa sepsis.

M. Klepser, D. Nicolau, R. Quintiliani, 1997, International journal of antimicrobial agents.

Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome

G. Weinstock, E. Sodergren, W. Dunne, 2022, Frontiers in Microbiology.

Directed carbapenemase testing is no longer just for Enterobacterales: cost, labor, and workflow assessment of expanding carbapenemase testing to carbapenem-resistant P. aeruginosa

F. Tenover, D. Nicolau, Amity L Roberts, 2023, Emerging microbes & infections.

Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa

D. Nicolau, C. Gill, 2022, The Journal of antimicrobial chemotherapy.

Evaluation of the Xpert Carba-R NxG Assay for Detection of Carbapenemase Genes in a Global Challenge Set of Pseudomonas aeruginosa Isolates

F. Tenover, D. Nicolau, I. Tickler, 2020, Journal of Clinical Microbiology.

Development and Application of a Pragmatic Algorithm to Guide Definitive Carbapenemase Testing to Identify Carbapenemase-Producing Pseudomonas aeruginosa

D. Nicolau, Tomefa E. Asempa, C. Gill, 2020, Antibiotics.

The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens.

D. Nicolau, D. Maglio, 2004, Methods and findings in experimental and clinical pharmacology.

Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections

D. Nicolau, 2015, Expert opinion on investigational drugs.

Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.

D. Xuan, D. Nicolau, R. Quintiliani, 2001, The Journal of antimicrobial chemotherapy.

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.

D. Nicolau, C. Nightingale, Chonghua Li, 2005, The Journal of antimicrobial chemotherapy.

Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance

D. Nicolau, M. Monogue, J. Kuti, 2016, Expert review of clinical pharmacology.

In vitro elution of ofloxacin from a bioabsorbable polymer.

B. Browner, D. Nicolau, R. Quintiliani, 1995, Acta orthopaedica Scandinavica.

Effect of Body Weight on Cefazolin and Vancomycin Trabecular Bone Concentrations in Patients Undergoing Total Joint Arthroplasty.

R. Schwarzkopf, Christina A. Sutherland, D. Nicolau, 2016, Surgical infections.

Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for Commonly Utilized Parenteral Agents against Methicillin-Susceptible Staphylococcus aureus: Focus on Ceftriaxone Discordance between Predictive Susceptibility and in Vivo Exposures

D. Nicolau, Nayon Y. Kang, S. Housman, 2015, Pathogens.

A Rationale for Maintaining Current Tigecycline Breakpoints as Established by the USA Food and Drug Administration

M. Wible, D. Nicolau, J. M. Bradley, 2015 .

Postantibiotic effect of trovafloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis in cerebrospinal fluid and broth culture media.

D. Nicolau, C. Nightingale, P. Tessier, 2000, Diagnostic microbiology and infectious disease.

In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure

Y. Hamada, D. Nicolau, J. Kuti, 2015, Antimicrobial Agents and Chemotherapy.

Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy.

P. Charifson, T. Grossman, Tiansheng Wang, 2014, Bioorganic & Medicinal Chemistry Letters.

Efficacy of Humanized Carbapenem and Ceftazidime Regimens against Enterobacteriaceae Producing OXA-48 Carbapenemase in a Murine Infection Model

P. Nordmann, D. Nicolau, D. Wiskirchen, 2013, Antimicrobial Agents and Chemotherapy.

Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.

D. Nicolau, J. Crandon, C. Urban, 2013, The Journal of antimicrobial chemotherapy.

Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection.

P. Barie, V. Ho, S. Jenkins, 2011, Surgical infections.

In Vivo Efficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase- Producing Klebsiella pneumoniae

D. Nicolau, C. Bulik, 2010, Antimicrobial Agents and Chemotherapy.

Comparison of the Activity of a Human Simulated, High-Dose, Prolonged Infusion of Meropenem against Klebsiella pneumoniae Producing the KPC Carbapenemase versus That against Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

Christina A. Sutherland, D. Nicolau, J. Kuti, 2009, Antimicrobial Agents and Chemotherapy.

Is all free time above the minimum inhibitory concentration the same: implications for beta-lactam in vivo modelling.

D. Nicolau, C. DeRyke, 2007, International journal of antimicrobial agents.

Tigecycline Displays In Vivo Bactericidal Activity against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae after 72-Hour Exposure Period

D. Nicolau, P. Tessier, 2012, Antimicrobial Agents and Chemotherapy.

Surgical site infections: does inadequate antibiotic therapy affect patient outcomes?

D. Nicolau, Aryun Kim, J. Kuti, 2009, Surgical infections.

Myoglobin Clearance during Continuous Veno-Venous Hemofiltration with or without Dialysis

D. Nicolau, C. Nightingale, S. Bernstein, 1998, The International journal of artificial organs.

Evaluation of Myoglobin Clearance during Continuous Hemofiltration in a Swine Model of Acute Renal Failure

D. Nicolau, Y. J. Feng, C. Nightingale, 1996, The International journal of artificial organs.

Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.

D. Nicolau, C. Nightingale, C. Babalola, 2004, The Journal of antimicrobial chemotherapy.

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia

J. D. De Waele, Elizabeth G. Rhee, D. Nicolau, 2020, The Journal of antimicrobial chemotherapy.

Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo

D. Nicolau, M. Monogue, A. Thabit, 2016, Antimicrobial Agents and Chemotherapy.

Deep and organ/space infections in patients undergoing elective colorectal surgery: incidence and impact on hospital length of stay and costs.

D. Nicolau, K. Eagye, Kathryn J. Eagye, 2009, American journal of surgery.

Effects of Adjunctive Treatment with Combined Cytokines in a Neutropenic Mouse Model of Multidrug‐Resistant Enterococcus faecalis Septicemia

D. Nicolau, C. Nightingale, C. Onyeji, 2001, Pharmacotherapy.

Comparative Pharmacokinetic and Pharmacodynamic Profile of Piperacillin/Tazobactam 3.375G Q4H and 4.5G Q6H

D. Xuan, D. Nicolau, R. Quintiliani, 2002, Chemotherapy.

Pleconaril, a Novel Antipicornaviral Agent

D. Nicolau, David P Nicolau, Naomi R Florea, 2003, Pharmacotherapy.

Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

L. Saiman, D. Nicolau, N. Neu, 2015, Diagnostic microbiology and infectious disease.

Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.

D. Nicolau, J. Kuti, M. Hagihara, 2012, Diagnostic microbiology and infectious disease.

Epidemiology and economics of adult patients hospitalized with urinary tract infections

D. Nicolau, J. Crandon, M. Nailor, 2016, Hospital practice.

Cerebral Spinal Fluid Penetration of Tigecycline in a Patient with Acinetobacter baumannii Cerebritis

D. Nicolau, M. Scheetz, L. Ray, 2010, The Annals of pharmacotherapy.

The Current State of Multidrug‐Resistant Gram‐Negative Bacilli in North America

D. Nicolau, Joseph L. Kuti, David P. Nicolau, 2008, Pharmacotherapy.

Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope.

D. Nicolau, Lindsay M. Avery, Elias M. Mullane, 2019, International journal of antimicrobial agents.

1245. In Vivo Efficacy of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) Against β-Lactamase-Producing (BLP) Gram-Negative Bacteria in a Neutropenic Murine Pneumonia Model

D. Nicolau, Kamilia Abdelraouf, Maxwell J. Lasko, 2020 .

In Vitro Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae

D. Nicolau, J. Kuti, M. Grupper, 2019, Antimicrobial Agents and Chemotherapy.

Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia

D. Nicolau, J. Kuti, Shawn H. MacVane, 2013, Antimicrobial Agents and Chemotherapy.

Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection.

D. Nicolau, Shawn H. MacVane, Lindsay O Tuttle, 2014, Journal of hospital medicine.

Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.

D. Nicolau, Lindsay M. Avery, 2018, International journal of antimicrobial agents.

Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient.

R. Bonomo, A. Hujer, D. Nicolau, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.

D. Nicolau, Tomefa E. Asempa, C. Gill, 2023, The Journal of antimicrobial chemotherapy.

In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model

D. Nicolau, Kamilia Abdelraouf, Matthew Gethers, 2022, The Journal of antimicrobial chemotherapy.

Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β-lactamase-producing Enterobacterales in the neutropenic murine thigh infection model.

D. Nicolau, Tomefa E. Asempa, C. Gill, 2020, The Journal of antimicrobial chemotherapy.

Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers

D. Nicolau, J. Crandon, Jared L. Crandon, 2013, Antimicrobial Agents and Chemotherapy.

Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa

Virna J. A. Schuck, D. Nicolau, J. Crandon, 2012, Antimicrobial Agents and Chemotherapy.

Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria

T. Welte, M. Bassetti, J. D. De Waele, 2015, Intensive Care Medicine.

Tigecycline for the Treatment of Multidrug-Resistant Klebsiella pneumoniae Meningitis

Patricia Dandache, D. Nicolau, G. Sakoulas, 2009 .

Erratum to “Quantitation of tigecycline, a novel glycylcycline, by liquid chromatography”: [J. Chromatogr. B 811 (2004) 225–229]

Christina A. Sutherland, D. Nicolau, C. Nightingale, 2005 .

Quantitation of tigecycline, a novel glycyclcycline, by liquid chromatography

Christina A. Sutherland, D. Nicolau, C. Nightingale, 2004 .

Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatography.

Christina A. Sutherland, D. Nicolau, C. Nightingale, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetics of Rifapentine in Subjects Seropositive for the Human Immunodeficiency Virus: a Phase I Study

R. Owens, M. Eller, D. Nicolau, 1999, Antimicrobial Agents and Chemotherapy.

Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline.

D. Nicolau, 2009, Expert opinion on pharmacotherapy.

Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia

R. Wunderink, R. Echols, D. Nicolau, 2021, The Journal of antimicrobial chemotherapy.

Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients.

D. Nicolau, J. Kuti, 2015, International journal of antimicrobial agents.

Pharmacokinetics of Meropenem 0.5 and 2 g Every 8 Hours as a 3‐Hour Infusion

Christina A. Sutherland, D. Nicolau, C. Nightingale, 2003, Pharmacotherapy.

Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model

D. Nicolau, Kamilia Abdelraouf, James M. Kidd, 2019, Antimicrobial Agents and Chemotherapy.

Monte Carlo Simulation Methodologies for β‐Lactam/β‐Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments

G. Stein, D. Nicolau, J. Kuti, 2020, Journal of clinical pharmacology.

Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections

D. Nicolau, R. Quintiliani, C. Nightingale, 1994, Antimicrobial Agents and Chemotherapy.

Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

D. Nicolau, J. Kuti, S. A. Almarzoky Abuhussain, 2018, Antimicrobial Agents and Chemotherapy.

Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.

D. Nicolau, Gregory Williams, Amira A Bhalodi, 2014, International journal of antimicrobial agents.

Optimized Cefiderocol Exposures in a Successfully Treated Critically Ill Patient with Polymicrobial Stenotrophomonas maltophilia Bacteremia and Pneumonia Receiving Continuous Venovenous Hemodiafiltration.

D. Nicolau, J. Kuti, A. Fratoni, 2021, International journal of antimicrobial agents.

Impact of Intraoperative Cell Salvage on Concentrations of Antibiotics Used for Surgical Prophylaxis

D. Nicolau, O. Serrano, J. Kuti, 2020, Antimicrobial Agents and Chemotherapy.

The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.

D. Nicolau, S. Kotapati, Erika C. Geissler, 2005, Intensive & critical care nursing.

Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.

D. Nicolau, S. Kotapati, Erika C. Geissler, 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Pharmacokinetics and Monte Carlo Simulations of Doripenem in Patients with Febrile Neutropenia

G. Stein, Apoorv Kalra, D. Nicolau, 2012, The Annals of pharmacotherapy.

Development of an HPLC method for the determination of doripenem in human and mouse serum.

Christina A. Sutherland, D. Nicolau, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Continuous infusion of beta-lactam antibiotics: a rational dosing approach.

D. Nicolau, R. Quintiliani, C. Nightingale, 1995, Connecticut medicine.

Pharmacokinetics of Doripenem in Infected Patients Treated Within and Outside the Intensive Care Unit

D. Nicolau, R. Quintiliani, J. Kuti, 2013, The Annals of pharmacotherapy.

In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against Pseudomonas aeruginosa

D. Nicolau, J. Crandon, C. Bulik, 2009, Antimicrobial Agents and Chemotherapy.

in Moderately to Morbidly Obese Adults Pharmacokinetics of Intravenous Linezolid

D. Nicolau, P. Papasavas, J. Kuti, 2014 .

Pharmacokinetics of minocycline and vancomycin in rabbits.

D. Nicolau, R. Quintiliani, C. Nightingale, 1993, Laboratory animal science.

Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000.

Stephen F Eckel, William Krebs, M. Zervos, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics and Pulmonary Disposition of Tedizolid and Linezolid in a Murine Pneumonia Model under Variable Conditions

D. Nicolau, J. Crandon, R. Keel, 2012, Antimicrobial Agents and Chemotherapy.

Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.

Christina A. Sutherland, D. Nicolau, 2015, Clinical therapeutics.

PHARMACOKINETIC AND ECONOMIC EVALUATION OF PIPERACILLIN/TAZOBACTAM ADMINISTERED AS EITHER CONTINUOUS OR INTERMITTENT INFUSION WITH ONCE-DAILY GENTAMIC IN

D. Nicolau, P. Ambrose, R. Quintiliani, 1999 .

Impact of Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella Species on Clinical Outcomes and Hospital Costs: A Matched Cohort Study

D. Nicolau, S. Kotapati, S. Y. Lee, 2006, Infection Control & Hospital Epidemiology.

Clostridium difficile infection in the elderly: an update on management

D. Nicolau, Tomefa E. Asempa, 2017, Clinical interventions in aging.

In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance

D. Nicolau, C. Bulik, H. Christensen, 2009, Antimicrobial Agents and Chemotherapy.

Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program.

D. Nicolau, J. Crandon, J. Kuti, 2009, International journal of antimicrobial agents.

Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.

Islam M. Ghazi, Y. Hamada, D. Nicolau, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli.

G. Stein, D. Nicolau, S. Schooley, 2008, International journal of antimicrobial agents.

Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model

D. Nicolau, J. Crandon, J. Kuti, 2010, Antimicrobial Agents and Chemotherapy.

Diagnostic and medical needs for therapeutic drug monitoring of antibiotics

A. van Belkum, D. Nicolau, J. Roberts, 2019, European Journal of Clinical Microbiology & Infectious Diseases.

Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis.

C H Nightingale, D. Nicolau, C. Nightingale, 1999, International journal of antimicrobial agents.

Short communication Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis

D. Nicolau, C. Nightingale, P. Tessier, 1999 .

Influence of ticlopidine on the development of experimental Staphylococcus aureus endocarditis.

D. Nicolau, R. Quintiliani, C. Nightingale, 1996, International journal of antimicrobial agents.

Patterns of adherence to antiretroviral medications: the value of electronic monitoring

J. Stoner, D. Nicolau, J. Ross, 2003, AIDS.

Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis

D. Nicolau, H. Huse, J. Kuti, 2021, Annals of Clinical Microbiology and Antimicrobials.

Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic.

D. Nicolau, C. Nightingale, J. Ross, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical use comparison of a semiautomated PCR with fluorescent ribotyping for typing of Clostridium difficile

D. Nicolau, M. Alam, C. D. Burnham, 2016, Archives of Microbiology.

The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship

M. Postma, R. Wunderink, T. Welte, 2017, Intensive Care Medicine.

Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in Clostridium difficile Infection

D. Nicolau, A. Thabit, 2015, Infectious diseases.

Successful treatment of a neonate with persistent vancomycin-resistant enterococcal bacteremia with a daptomycin-containing regimen

H. Seiden, L. Rubin, D. Nicolau, 2008, Infection and drug resistance.

Influence of adjunctive interferon-gamma on treatment of gentamicin- and vancomycin-resistant Enterococcus faecalis infection in mice.

D. Nicolau, R. Quintiliani, C. Nightingale, 1999, International journal of antimicrobial agents.

In Vitro Evaluation of Novel Compounds against Selected Resistant Pseudomonas aeruginosa Isolates

Christina A. Sutherland, D. Nicolau, S. Housman, 2011, Antimicrobial Agents and Chemotherapy.

The challenges of patient satisfaction: influencing factors and the patient – provider relationship in the United States

D. Nicolau, Arlinda Baummer - Carr, 2017, Expert review of anti-infective therapy.

Optimizing Antibiotic Pharmacodynamics for Clinical Practice

D. Nicolau, J. Kuti, K. Connors, 2013 .

Comparison of 2002–2006 OPTAMA Programs for US Hospitals: Focus on Gram-Negative Resistance

Ronald N. Jones, D. Nicolau, J. Crandon, 2009, The Annals of pharmacotherapy.

Interferon-gamma effects on activities of gentamicin and vancomycin against Enterococcus faecalis resistant to the drugs: an in vitro study with human neutrophils.

D. Nicolau, C. Nightingale, C. Onyeji, 1999, International journal of antimicrobial agents.

Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women

D. Nicolau, E. Salerno, S. Housman, 2014, Antimicrobial Agents and Chemotherapy.

Comparative Efficacies of Human Simulated Exposures of Tedizolid and Linezolid against Staphylococcus aureus in the Murine Thigh Infection Model

D. Nicolau, J. Crandon, P. Tessier, 2012, Antimicrobial Agents and Chemotherapy.

Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant Staphylococcus aureus Pneumonia

M. Antonelli, P. Pelosi, A. Artigas, 2020, Antimicrobial Agents and Chemotherapy.

In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa

D. Nicolau, M. Nailor, K. Goodlet, 2017, Antimicrobial Agents and Chemotherapy.

In Vivo Efficacy of a Human-Simulated Regimen of Ceftaroline Combined with NXL104 against Extended-Spectrum-β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Enterobacteriaceae

D. Nicolau, D. Wiskirchen, J. Crandon, 2011, Antimicrobial Agents and Chemotherapy.

Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae.

D. Nicolau, D. Wiskirchen, J. Crandon, 2013, International journal of antimicrobial agents.

Reply to Cheng and Chuang.

C. Arias, M. Weisser, D. Nicolau, 2019, Clinical Infectious Diseases.

Antibiotic Tissue Penetration in Diabetic Foot Infections A Review of the Microdialysis Literature and Needs for Future Research.

D. Nicolau, D. Wiskirchen, A. Ray, 2015, Journal of the American Podiatric Medical Association.

Tigecycline penetration into skin and soft tissue.

J. Kepros, G. Stein, D. Nicolau, 2011, Surgical infections.

Epidemiology, treatment, and economics of patients presenting to the emergency department for skin and soft tissue infections

D. Nicolau, M. Nailor, Kristin E. Linder, 2017, Hospital practice.

Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2019, Journal of Clinical Microbiology.

Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.

D. Nicolau, A. Thabit, J. Crandon, 2016, International journal of antimicrobial agents.

Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis.

D. Nicolau, M. Monogue, A. Thabit, 2018, International journal of antimicrobial agents.

Pharmacokinetics of dalbavancin in plasma and skin blister fluid.

D. Nicolau, J. Dowell, M. Buckwalter, 2007, The Journal of antimicrobial chemotherapy.

Cefazolin potency against methicillin-resistant Staphylococcus aureus: a microbiologic assessment in support of a novel drug delivery system for skin and skin structure infections

D. Nicolau, B. Silberg, 2017, Infection and drug resistance.

Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.

Islam M. Ghazi, D. Nicolau, R. Quintiliani, 2016, International journal of antimicrobial agents.

Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy

P. Burcham, K. Bauer, D. Nicolau, 2016, Pharmacotherapy.

Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration

J. Gonzales, D. Nicolau, Shailly Mehrotra, 2015, Antimicrobial Agents and Chemotherapy.

Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy.

Christina A. Sutherland, D. Nicolau, 2017, Journal of thoracic disease.

Duration of antibiotic therapy for Enterobacterales and Pseudomonas aeruginosa: a review of recent evidence

D. Nicolau, Sergio Reyes, Julia Kostka, 2021, Current opinion in infectious diseases.

Pharmacodynamic Assessment of Ertapenem (MK-0826) against Streptococcuspneumoniae in a Murine Neutropenic Thigh Infection Model

D. Xuan, D. Nicolau, C. Nightingale, 2002, Antimicrobial Agents and Chemotherapy.

Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies.

Christina A. Sutherland, D. Nicolau, J. Kuti, 2010, Diagnostic microbiology and infectious disease.

Pharmacodynamics of daptomycin when prescribed in combination with other antibiotics for treatment of enterococcal bacteremia.

C. Arias, M. Weisser, D. Nicolau, 2019, International journal of antimicrobial agents.

Linezolid penetration into wound tissue of two diabetic patients before and after hyperbaric oxygen therapy.

D. Nicolau, J. Kuti, Larry A Suecof, 2011, Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc.

Cost‐Effectiveness of Telavancin versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections

D. Nicolau, S. Barriere, J. Kuti, 2008, Pharmacotherapy.

Redefining Success for VAP: 360-Degree Approach

D. Nicolau, D. Burgess, K. Rodvold, 2009, Journal of Managed Care Pharmacy : JMCP.

Bronchopulmonary disposition of IV cefepime/taniborbactam (2–0.5 g) administered over 2 h in healthy adult subjects

D. Nicolau, E. Salerno, J. Kuti, 2023, The Journal of antimicrobial chemotherapy.

parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.

G. Doern, D. Nicolau, Xiaoli Du, 2007, International journal of antimicrobial agents.

Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.

D. Nicolau, Xiaoli Du, C. DeRyke, 2006, The Journal of antimicrobial chemotherapy.

The challenge of prescribing treatment for respiratory tract infections.

D. Nicolau, 2000, The American journal of managed care.

Detection of Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli with Current Automated Susceptibility Test Systems

D. Nicolau, M. Monogue, S. Brecher, 2017, Infection Control & Hospital Epidemiology.

Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible

D. Calfee, L. Westblade, S. Jenkins, 2018, Open forum infectious diseases.

Prevalence, patient characteristics and outcomes of a novel piperacillin/tazobactam-resistant, pan-β-lactam-susceptible phenotype in Enterobacteriaceae: implications for selective reporting.

D. Nicolau, A. Thabit, J. Kuti, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli

D. Nicolau, M. Monogue, 2016, Antimicrobial Agents and Chemotherapy.

Detection of Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli with Current Automated Susceptibility Test Systems

D. Nicolau, M. Monogue, S. Brecher, 2017, Infection Control & Hospital Epidemiology.

Molecular Characterization of Piperacillin-Tazobactam (TZP) Resistant Escherichia coli Susceptible to Cephalosporins, Monobactams, and Carbapenems

S. Jenkins, B. Kreiswirth, D. Nicolau, 2015 .

In vitro blood culture bottle inoculation of whole blood with clinically relevant antibiotic concentrations: a word of caution

D. Nicolau, J. Kuti, M. Grupper, 2017, European Journal of Clinical Microbiology & Infectious Diseases.

Development and characterization of a new swine model of invasive pneumococcal pneumonia

F. Pagliara, M. Schultz, A. Artigas, 2021, Lab Animal.

Development and characterization of a new swine model of invasive pneumococcal pneumonia

F. Pagliara, M. Schultz, A. Artigas, 2021, Lab Animal.

Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient

D. Nicolau, D. Maglio, C. DeRyke, 2005, Expert opinion on pharmacotherapy.

Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters

Christina A. Sutherland, D. Nicolau, P. Kavaliauskas, 2021, Antimicrobial agents and chemotherapy.

Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis

P. Cyr, D. Nicolau, T. Lodise, 2016, Journal of managed care & specialty pharmacy.

Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis

P. Cyr, D. Nicolau, T. Lodise, 2015, Clinical Drug Investigation.

Simultaneous determination of ticarcillin and clavulanate in rabbit serum and tissue cage fluid by liquid chromatography.

D. Nicolau, C. Nightingale, Chonghua Li, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Infusion Phlebitis

D. Nicolau, R. Quintiliani, C. Nightingale, 1998, Clinical drug investigation.

Application of Pharmacodynamic Profiling for the Selection of Optimal β-lactam Regimens in a Large University Hospital.

P. Kiratisin, D. Nicolau, Thitiya Yungyuen, 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations.

D. Nicolau, J. Kuti, Ana Motos, 2019, International journal of antimicrobial agents.

IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics

D. Nicolau, C. Nightingale, J. Kuti, 2004 .

Pharmacodynamic Assessment of Gatifloxacin against Streptococcus pneumoniae

D. Xuan, D. Nicolau, Dadong Li, 2001, Antimicrobial Agents and Chemotherapy.

Mononuclear and Polymorphonuclear Leukocyte Dispositions of Clarithromycin and Azithromycin in AIDS Patients Requiring Mycobacterium avium Complex Prophylaxis

D. Nicolau, C. Nightingale, Chonghua Li, 1999, Antimicrobial Agents and Chemotherapy.

In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii

R. Echols, D. Nicolau, Y. Yamano, 2023, The Journal of antimicrobial chemotherapy.

Bactericidal In Vitro Activity of a Tissue-Achievable Concentration of Cefazolin against Methicillin-Resistant Staphylococcus aureus.

D. Nicolau, I. Chen, B. Silberg, 2020, Surgical infections.

Pharmacokinetics of Clarithromycin Extended-Release (ER) Tablets in Patients with AIDS

M. Jacobson, F. Aweeka, Christina A. Sutherland, 2005, HIV clinical trials.

Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs).

D. Nicolau, C. Nightingale, C. Babalola, 2005, The Journal of antimicrobial chemotherapy.

Comparison of azithromycin leukocyte disposition in healthy volunteers and volunteers with AIDS.

D. Xuan, R. Owens, D. Nicolau, 2000, International journal of antimicrobial agents.

1652. Sulbactam against Acinetobacter baumannii Pneumonia: Pharmacokinetic/Pharmacodynamic Appraisal of Current Dosing Recommendations

D. Nicolau, Kamilia Abdelraouf, J. Kuti, 2022, Open Forum Infectious Diseases.

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa

A. Oliver, D. Nicolau, C. Gill, 2022, The Journal of antimicrobial chemotherapy.

Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Stenotrophomonas maltophilia between in vitro chemostat and in vivo murine infection models.

D. Nicolau, Kamilia Abdelraouf, Rio Nakamura, 2021, The Journal of antimicrobial chemotherapy.

Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosa

D. Nicolau, J. Crandon, C. McPherson, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic rationale for short-duration antibacterial therapy.

D. Nicolau, 2002, The Journal of infection.

Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its “Sell-By Date” in an Era of New Antibiotics and Regional Carbapenemase Epidemiology

D. Livermore, K. Hopkins, D. Nicolau, 2020 .

'CRE, CRO, CPE and CPO': terminology past its 'sell-by-date' in an era of new antibiotics and regional carbapenemase epidemiology.

D. Livermore, K. Hopkins, D. Nicolau, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?

T. Welte, G. Dimopoulos, D. Nicolau, 2016, Expert review of respiratory medicine.

Early Antibiotic Discontinuation in Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative Bronchoscopy Cultures*

D. Nicolau, M. Nailor, J. Kuti, 2013, Critical care medicine.

Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia.

D. Nicolau, J. Kuti, K. Eagye, 2009, Seminars in respiratory and critical care medicine.

Oral Absorption of Trimethoprim‐Sulfamethoxazole in Patients with AIDS

M. Klepser, D. Nicolau, C. Nightingale, 1996, Pharmacotherapy.

Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis

D. Nicolau, Ashley K. Shepard, J. Kuti, 2022, The Journal of antimicrobial chemotherapy.

Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance

M. Rizk, D. Nicolau, J. Roberts, 2023, JAC-antimicrobial resistance.

Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.

D. Nicolau, J. Kuti, D. Maglio, 2005, Clinical therapeutics.

Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.

D. Nicolau, Hui Wang, Y. Ni, 2007, International journal of antimicrobial agents.

Pharmacokinetics of Cefprozil in Plasma and Middle Ear Fluid

R. Dagan, Christina A. Sutherland, D. Nicolau, 2007, Paediatric drugs.

Optimal Cefazolin Prophylactic Dosing for Bariatric Surgery: No Need for Higher Doses or Intraoperative Redosing

B. Cunha, C. Brathwaite, D. Nicolau, 2017, Obesity Surgery.

Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.

Bryan M. Li, A. Stepan, J. Aubrecht, 2013, Journal of medicinal chemistry.

Erratum: Antimicrobials: A global alliance for optimizing their rational use in intra-abdominal infections (AGORA). [World J Emerg Surg. 11, (2016) (33)] DOI: 10.1186/s13017-016-0089-y

M. Boermeester, Yonghong Xiao, J. Vincent, 2017 .

Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.

D. Nicolau, J. Kuti, C. Bulik, 2010, Clinical therapeutics.

Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure.

D. Nicolau, Ryan W. Stevens, B. Westley, 2019, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

In vitro potency of amikacin and comparators against E. coli,K. pneumoniae and P. aeruginosa respiratory and blood isolates

Christina A. Sutherland, D. Nicolau, Jamie E. Verastegui, 2016, Annals of Clinical Microbiology and Antimicrobials.

Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study*

M. Antonelli, P. Pelosi, F. Blasi, 2019, Critical care medicine.

Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia

P. Pelosi, J. Vila, F. Pagliara, 2023, Critical Care.

Pharmacokinetics of cefotaxime in healthy volunteers and patients.

D. Nicolau, R. Quintiliani, C. Nightingale, 1995, Diagnostic microbiology and infectious disease.

Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of Escherichia coli and Klebsiella pneumoniae Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding Resins

D. Nicolau, J. Kuti, I. Chen, 2019, Journal of Clinical Microbiology.

Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.

D. Nicolau, K. Eagye, 2011, The Journal of antimicrobial chemotherapy.

Absence of Association between Use of Ertapenem and Change in Antipseudomonal Carbapenem Susceptibility Rates in 25 Hospitals

D. Nicolau, K. Eagye, Kathryn J. Eagye, 2010, Infection Control & Hospital Epidemiology.

Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae

D. Nicolau, M. Nailor, J. Kuti, 2014, Scandinavian journal of infectious diseases.

In vitro potency of amikacin and comparators against E. coli,K. pneumoniae and P. aeruginosa respiratory and blood isolates

Christina A. Sutherland, D. Nicolau, Jamie E. Verastegui, 2016, Annals of Clinical Microbiology and Antimicrobials.

Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.

D. Nicolau, Tomefa E. Asempa, Maxwell J. Lasko, 2021, The Journal of antimicrobial chemotherapy.

Imipenem/Cilastatin/Relebactam Alone and in Combination against Pseudomonas aeruginosa in the In Vitro Pharmacodynamic Model

D. Nicolau, J. Kuti, I. Chen, 2020, Antimicrobial Agents and Chemotherapy.

In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model

D. Nicolau, M. Monogue, Kamilia Abdelraouf, 2019, Antimicrobial Agents and Chemotherapy.

Comparison of Meropenem MICs and Susceptibilities for Carbapenemase-Producing Klebsiella pneumoniae Isolates by Various Testing Methods

S. Jenkins, D. Nicolau, Catharine C. Bulik, 2010, Journal of Clinical Microbiology.

Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.

D. Kontoyiannis, D. Nicolau, Micah M. Bhatti, 2016, The Pediatric infectious disease journal.

Stability of doripenem, imipenem and meropenem at elevated room temperatures.

Christina A. Sutherland, D. Nicolau, J. Crandon, 2011, International journal of antimicrobial agents.

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model

D. Nicolau, Kamilia Abdelraouf, 2023, The Journal of antimicrobial chemotherapy.

Pharmacologic optimization of antibiotics for Gram-negative infections.

D. Nicolau, C. Gill, 2019, Current opinion in infectious diseases.

Comment on: An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.

D. Nicolau, Kamilia Abdelraouf, S. Bhagwat, 2021, The Journal of antimicrobial chemotherapy.

1336. Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant Acinetobacter baumannii (CR-ACBN) in the Neutropenic Murine Thigh Infection Model

D. Nicolau, Kamilia Abdelraouf, Lindsay M. Avery, 2018, Open Forum Infectious Diseases.

Characterizing In Vivo Pharmacodynamics of Carbapenems against Acinetobacter baumannii in a Murine Thigh Infection Model To Support Breakpoint Determinations

D. Nicolau, J. Crandon, Shawn H. MacVane, 2013, Antimicrobial Agents and Chemotherapy.

Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision.

D. Nicolau, J. Kuti, A. Fratoni, 2021, The Journal of antimicrobial chemotherapy.

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.

D. Nicolau, C. Nightingale, J. Kuti, 2004, Clinical therapeutics.

Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in Pseudomonas aeruginosa: Validation in a Multicenter German Cohort.

H. Seifert, D. Nicolau, M. Kresken, 2021, Microbial drug resistance.

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.

D. Nicolau, Jennifer E. Girotto, Brittany A Rodriguez, 2018, Current pediatric reviews.

To Add or Not To Add Polysorbate 80: Impact on Colistin MICs for Clinical Strains of Enterobacteriaceae and Pseudomonas aeruginosa and Quality Controls

Christina A. Sutherland, D. Nicolau, 2014, Journal of Clinical Microbiology.

Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints.

D. Nicolau, J. Kuti, A. Fratoni, 2022, The Journal of antimicrobial chemotherapy.

Serum bactericidal activity of ceftizoxime and ceftriaxone against pathogens associated with community-acquired and nosocomial pneumonias.

D. Nicolau, R. Quintiliani, C. Nightingale, 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Cefiderocol is Not Sequestered in an Ex Vivo Extracorporeal Membrane Oxygenation (ECMO) Circuit

D. Nicolau, J. Kuti, J. Gluck, 2022, European Journal of Drug Metabolism and Pharmacokinetics.

609. In vivo efficacy of human simulated exposures of cefiderocol (FDC) in combination with ceftazidime/avibactam (CZA) or meropenem (MEM) using in a 72 hour murine thigh infection model

R. Echols, D. Nicolau, Y. Yamano, 2022, Open Forum Infectious Diseases.

Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration

A. Mochon, D. Nicolau, N. Nicolasora, 2021, Open forum infectious diseases.

Ceftibuten: An Overview

R. Owens, D. Nicolau, C. Nightingale, 1997, Pharmacotherapy.

Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: A report from the OPTAMA Program

D. Nicolau, J. Kuti, Heather K. Sun, 2005, Critical care medicine.

What’s new in antimicrobial use and resistance in critically ill patients?

T. Calandra, M. Bassetti, D. Nicolau, 2014, Intensive Care Medicine.

Tetracycline-induced pancreatitis.

D. Nicolau, J. Kline, D. E. Mengedoht, 1991, American Journal of Gastroenterology.

A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin

K. Garey, D. Nicolau, M. Khaleduzzaman, 2016, Annals of Clinical Microbiology and Antimicrobials.

Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin

D. Nicolau, R. Quintiliani, A. Thabit, 2015, Infection Control & Hospital Epidemiology.

Association of healthcare exposure with acquisition of different Clostridium difficile strain types in patients with recurrent infection or colonization after clinical resolution of initial infection.

D. Nicolau, C. D. Burnham, A. Thabit, 2016, The Journal of hospital infection.

Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections

D. Nicolau, M. Gopalakrishnan, E. Heil, 2020, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic optimization of β-lactams in the patient care setting

D. Nicolau, 2008, Critical care.

AAC 05473-11 Version 2 2 3 4 In Vitro Pharmacodynamics of Vancomycin and Cefazolin Alone and in 5 Combination against Methicillin-Resistant Staphylococcus aureus 6 7

D. Nicolau, D. Wiskirchen, J. Kuti, 2011 .

Drug Utilization Evaluation of Imipenem/Cilastatin in Patients with Renal Dysfunction

D. Nicolau, Maureen L. Sheakely, Suzanne I. Agner, 1993, The Annals of Pharmacotherapy.

Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients

A. Torres, D. Nicolau, P. Castro, 2019, Critical Care.

Pharmacodynamic Assessment of Cefprozil againstStreptococcus pneumoniae: Implications for Breakpoint Determinations

M. Zhong, D. Nicolau, C. Nightingale, 2000, Antimicrobial Agents and Chemotherapy.

Comparison of In Vivo and In Vitro Pharmacodynamics of a Humanized Regimen of 600 Milligrams of Ceftaroline Fosamil Every 12 Hours against Staphylococcus aureus at Initial Inocula of 106 and 108 CFU per Milliliter

D. Nicolau, G. Zhanel, J. Crandon, 2014, Antimicrobial Agents and Chemotherapy.

Use of continuous infusion ceftolozane–tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis

D. Nicolau, P. Bookstaver, J. Hucks, 2019, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Pharmacodynamic study of β-lactams alone and in combination with β-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible β-lactamase

D. Nicolau, R. Quintiliani, C. Nightingale, 2004 .

Cefazolin dosing for surgical prophylaxis in morbidly obese patients.

P. Barie, C. Towe, A. Pomp, 2012, Surgical Infections.

Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia

M. Antonelli, P. Pelosi, M. Kollef, 2020, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Ticlopidine in the Rabbit

F. Vallée, D. Nicolau, C. Nightingale, 1999, The Journal of pharmacy and pharmacology.

Development of an HPLC Method for the Determination of Meropenem/Vaborbactam in Biological and Aqueous Matrixes.

Christina A. Sutherland, D. Nicolau, 2020, Journal of chromatographic science.

Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education

D. Nicolau, K. Keyloun, M. Nailor, 2018, Open forum infectious diseases.

Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).

D. Nicolau, J. Kuti, J. Gluck, 2022, International journal of antimicrobial agents.

The prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence.

M. Kollef, D. Greenberg, R. Echols, 2023, International journal of antimicrobial agents.

Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.

D. Nicolau, J. Kuti, Sergio Reyes, 2019, Clinical therapeutics.

Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration.

D. Nicolau, J. Kuti, Tomefa E. Asempa, 2017, Clinical therapeutics.

Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration.

D. Nicolau, J. Kuti, P. Tessier, 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.

Y. Hamada, D. Nicolau, A. Thabit, 2017, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.

D. Nicolau, A. Thabit, J. Kuti, 2017, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous hemodiafiltration: A patient case and literature review.

Christina A. Sutherland, D. Nicolau, Ahmed Mahmoud, 2020, Journal of global antimicrobial resistance.

Potentiation of Antibacterial Activity of the MB-1 Siderophore-Monobactam Conjugate Using an Efflux Pump Inhibitor

D. Nicolau, J. Crandon, C. McPherson, 2015, Antimicrobial Agents and Chemotherapy.

Potentiation of antibacterial activity of the MB-1 siderophore-monobactam conjugate using 1 an efflux pump inhibitor 2 3 4

D. Nicolau, J. Crandon, C. McPherson, 2015 .

In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing Enterobacteriaceae.

Christina A. Sutherland, D. Nicolau, Lindsay M. Avery, 2019, Diagnostic microbiology and infectious disease.

Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory

D. Nicolau, Lindsay M. Avery, 2018, Journal of Antimicrobial Chemotherapy.

Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa

D. Nicolau, Lindsay M. Avery, Elias M. Mullane, 2019, Antimicrobial Agents and Chemotherapy.

Review Pharmacodynamic optimization of β-lactams in the patient care

D. Nicolau, 2008 .

In memoriam: John P. Quinn, MD.

L. Rice, R. Weinstein, R. Bonomo, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

KPC Presence in Pseudomonas aeruginosa Has Minimal Impact on the In Vivo Efficacy of Carbapenem Therapy

D. Nicolau, J. Crandon, C. Urban, 2012, Antimicrobial Agents and Chemotherapy.

Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model

A. Torres, D. Nicolau, J. Kuti, 2018, Antimicrobial Agents and Chemotherapy.

Empiric Treatment of Multidrug‐Resistant Burkholderia cepacia Lung Exacerbation in a Patient with Cystic Fibrosis: Application of Pharmacodynamic Concepts to Meropenem Therapy

D. Nicolau, K. Moss, J. Kuti, 2004, Pharmacotherapy.

Stability of meropenem in a portable infusion device in a cold pouch.

M. Zhong, D. Nicolau, P. Ambrose, 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

When "S" does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection.

D. Nicolau, J. Kuti, E. L. Gillespie, 2005, Connecticut medicine.

Utilization of extended-spectrum beta-lactamase (ESBL) detection systems in microbiology laboratories: survey of Connecticut hospitals from 1998-2002.

D. Nicolau, C. Nightingale, N. Barrett, 2003, Connecticut medicine.

Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitals.

D. Nicolau, D. Sahm, J. Kuti, 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections.

D. Nicolau, D. Melnick, J. Kuti, 2006, International journal of antimicrobial agents.

The paradoxical in vivo activity of β-lactams against metallo-β-lactamase-producing Enterobacterales is not restricted to carbapenems.

D. Nicolau, Kamilia Abdelraouf, Sergio Reyes, 2020, The Journal of antimicrobial chemotherapy.

Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window.

D. Nicolau, M. Scheetz, Cristina M Miglis, 2017, International journal of antimicrobial agents.

Metallo-β-lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods.

D. Nicolau, Kamilia Abdelraouf, Tomefa E. Asempa, 2020, The Journal of antimicrobial chemotherapy.

A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004

J. Quinn, S. Lockhart, G. Doern, 2007, Annals of Clinical Microbiology and Antimicrobials.

Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency

D. Nicolau, J. Zuckerman, Minkey Wungwattana, 2017, Respiratory medicine case reports.

Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections.

D. Nicolau, M. Dowzicky, J. Kuti, 2008, Surgical infections.

Pharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitals.

D. Nicolau, G. Zhanel, S. Zelenitsky, 2011, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.

D. Nicolau, R. Quintiliani, C. Nightingale, 2000, The Journal of antimicrobial chemotherapy.

Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-Susceptible, Carbapenem-Resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.

D. Nicolau, C. Gill, 2022, Clinical therapeutics.

Evaluation of a disease state management guideline for urinary tract infection.

D. Nicolau, J. Crandon, M. Nailor, 2016, International journal of antimicrobial agents.

Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.

G. Stein, D. Nicolau, D. Havlichek, 2019, Surgical infections.

Pharmacokinetics and Pharmacodynamics of Continuous and Intermittent Ceftazidime during the Treatment of Nosocomial Pneumonia

D. Nicolau, R. Quintiliani, C. Nightingale, 1999 .

CONTINUOUS VS. INTERMITTENT INFUSION OF CEFUROXIME FOR THE TREATMENT OF COMMUNITY‐ACQUIRED PNEUMONIA

D. Nicolau, P. Ambrose, C. Nightingale, 1998 .

Optimal Dosing of Piperacillin‐Tazobactam for the Treatment of Pseudomonas aeruginosa Infections: Prolonged or Continuous Infusion?

Aryun Kim, Christina A. Sutherland, D. Nicolau, 2007, Pharmacotherapy.

Treatment of Serratia marcescens Meningitis with Prolonged Infusion of Meropenem

D. Nicolau, R. Quintiliani, J. Kuti, 2007, The Annals of pharmacotherapy.

Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens.

R. Owens, D. Nicolau, P. Ambrose, 2001, International journal of antimicrobial agents.

Comparison of Bactericidal Activities of Intermittent and Continuous Infusion Dosing of Vancomycin against Methicillin‐Resistant Staphylococcus aureus and Enterococcus faecalis

M. Klepser, D. Nicolau, R. Quintiliani, 1998, Pharmacotherapy.

Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system

Islam M. Ghazi, D. Nicolau, M. Grupper, 2017, Annals of Clinical Microbiology and Antimicrobials.

Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime.

D. Nicolau, R. Quintiliani, C. Nightingale, 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Cefazolin Prophylaxis in Obese Women Undergoing Cesarean Delivery: A Randomized Controlled Trial

D. Rouse, D. Nicolau, L. Maggio, 2015, Obstetrics and gynecology.

Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery.

D. Nicolau, J. Kuti, L. Maggio, 2017, Journal of clinical pharmacology.

In Vivo Pharmacodynamic Modeling for Drug Discovery

D. Nicolau, J. Crandon, Jared L. Crandon, 2012 .

Cefepime in vivo activity against carbapenem-resistant Enterobacterales that test as cefepime susceptible or susceptible-dose dependent in vitro: implications for clinical microbiology laboratory and clinicians.

D. Nicolau, P. Simner, Tomefa E. Asempa, 2023, The Journal of antimicrobial chemotherapy.

Validation of a Dosing Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass.

K. Thom, D. Nicolau, T. Dowling, 2015, Surgical infections.

Characterization of the Penetration of Garenoxacin into the Breast Milk of Lactating Women

D. Gajjar, D. Nicolau, A. Bello, 2004, Journal of clinical pharmacology.

Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C.

Christina A. Sutherland, D. Nicolau, J. Kuti, 2014, American Journal of Health-System Pharmacy.

Peritoneal Fluid Penetration of Tigecycline

M. Postelnick, G. Noskin, D. Nicolau, 2006, The Annals of pharmacotherapy.

Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics

D. Nicolau, M. Nailor, M. Zmarlicka, 2015, Infection and Drug Resistance.

Bronchoscopic Evaluation of Moxifloxacin Therapy in Acute Exacerbations of Chronic Bronchitis Previously Treated With Azithromycin

R. Baughman, D. Nicolau, D. Winget, 2007 .

The Use of Scoring Systems to Predict Prognosis in Patients With Ventilator-associated Pneumonia

D. Nicolau, D. Wiskirchen, J. Kuti, 2011 .

Erratum to: Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)

M. Boermeester, Yonghong Xiao, Soumitra R. Eachempati, 2017, World Journal of Emergency Surgery.

Impact of Order-Set Modifications and Provider Education Following Guideline Updates on Broad-Spectrum Antibiotic Use in Patients Admitted With Community Acquired Pneumonia

D. Nicolau, J. Kuti, C. Dempsey, 2021, Hospital pharmacy.

In Vivo Efficacy of Humanized Ceftaroline Fosamil-Avibactam Exposures in a Polymicrobial Infection Model

D. Nicolau, J. Crandon, A. A. Bhalodi, 2013, Antimicrobial Agents and Chemotherapy.

Management of Pneumonia in the Pediatric Critical Care Unit: An Area for Antimicrobial Stewardship.

D. Nicolau, Aimee M. Dassner, Jennifer E. Girotto, 2017, Current pediatric reviews.

An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes

D. Nicolau, A. Thabit, 2016 .

Infection and Drug Resistance Dovepress an Exploratory Study to Evaluate Clostridium Difficile Polymerase Chain Reaction Ribotypes and Infection Outcomes

D. Nicolau, A. Thabit, 2022 .

In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model.

D. Nicolau, Kamilia Abdelraouf, Sergio Reyes, 2020, The Journal of antimicrobial chemotherapy.

Pseudomonas aeruginosa is not just in the intensive care unit any more: Implications for empirical therapy*

D. Nicolau, K. Eagye, M. Banevicius, 2012, Critical Care Medicine.

In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.

Christina A. Sutherland, D. Nicolau, J. Kuti, 2009, Clinical therapeutics.

Defining Extended Spectrum β-Lactamases: Implications of Minimum Inhibitory Concentration-Based Screening Versus Clavulanate Confirmation Testing

Christina A. Sutherland, D. Nicolau, J. Crandon, 2015, Infectious Diseases and Therapy.

Annals of Clinical Microbiology and Antimicrobials Open Access a Pharmacodynamic Analysis of Resistance Trends in Pathogens from Patients with Infection in Intensive Care Units in the United States between 1993 and 2004

J. Quinn, S. Lockhart, G. Doern, 2022 .

Impact of a Pharmacist-Managed Procalcitonin Program on COVID-19 Respiratory Tract Infection Outcomes and Health Care Resource Utilization

D. Nicolau, J. Kuti, A. Kois, 2022, Open forum infectious diseases.

In vitro potency of amikacin against carbapenem-resistant Pseudomonas aeruginosa: A target for nebulization strategy?

D. Nicolau, C. Kiffer, A. C. Pignatari, 2022, Brazilian Journal of Infectious Diseases.

In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure

Y. Hamada, D. Nicolau, J. Kuti, 2015, Antimicrobial Agents and Chemotherapy.

In Vitro Pharmacodynamics of Human Simulated Exposures of Ceftaroline and Daptomycin against MRSA, hVISA, and VISA with and without Prior Vancomycin Exposure

D. Nicolau, J. Kuti, A. A. Bhalodi, 2013, Antimicrobial Agents and Chemotherapy.

Implementation of a once-daily aminoglycoside program in a large community-teaching hospital.

D. Nicolau, R. Quintiliani, C. Nightingale, 1995, Hospital pharmacy.

Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.

D. Nicolau, G. Furtado, E. Medeiros, 2015, Revista da Sociedade Brasileira de Medicina Tropical.

Questioning the paradigm: monotherapy vs combination antimicrobial therapy for treatment of Pseudomonas aeruginosa.

D. Nicolau, J. Kuti, C. A. Deryke, 2005, Connecticut medicine.

Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus Strains

D. Nicolau, P. Tessier, Somvadee Laohavaleeson, 2008, Antimicrobial Agents and Chemotherapy.

Treatment of Clostridium difficile-associated disease (CDAD).

D. Nicolau, C. Nightingale, J. Kuti, 2003, Connecticut medicine.

Review of antimicrobial use and considerations in the elderly population

D. Nicolau, Angela Giarratano, S. Green, 2018 .

Review of antimicrobial use and considerations in the elderly population

D. Nicolau, Angela Giarratano, S. Green, 2018 .

Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient

V. Waters, D. Nicolau, J. Zuckerman, 2015, Antimicrobial Agents and Chemotherapy.

Clinical and economic implications of urinary tract infections

D. Nicolau, Samantha N. Steiger, Rachel R Comito, 2017, Expert review of pharmacoeconomics & outcomes research.

Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?

T. Welte, G. Dimopoulos, D. Nicolau, 2016, Expert review of respiratory medicine.

Selection of prophylactic antimicrobial agent may affect incidence of infection in small bowel and colorectal surgery.

D. Nicolau, K. Eagye, 2011, Surgical infections.

Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy

D. Ehmann, A. Eakin, D. Nicolau, 2015, Antimicrobial Agents and Chemotherapy.

Potentiation of Antibacterial Activity of the MB-1 Siderophore-Monobactam Conjugate Using an Efflux Pump Inhibitor

D. Nicolau, C. McPherson, A. Tomaras, 2015, Antimicrobial Agents and Chemotherapy.

Pharmacodynamic considerations for the selection of oral cephalosporins in the treatment of rhinosinusitis.

D. Nicolau, P. K. Dandekar, 2002, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Serum Bactericidal Activity of Levofloxacin and Moxifloxacin Against Strains of Streptococcus pneumoniae With First-Step Mutations

Grace K. Kim, G. Stein, L. Dybas, 2011 .

Intelligent dosing of antimicrobials.

D. Nicolau, R. Quintiliani, C. Nightingale, 1994, Current clinical topics in infectious diseases.

The pharmacodynamics of aminoglycosides.

D. Nicolau, R. Quintiliani, C. Nightingale, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Influence of automated screening and confirmation of extended-spectrum beta-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics.

D. Nicolau, J. Kuti, J. Aslanzadeh, 2008, Journal of medical microbiology.

The costs of burn care: an analysis with an emphasis on the use of parenteral antimicrobials.

D. Nicolau, R. White, L. Friedrich, 1994, The Journal of burn care & rehabilitation.

Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection.

D. Nicolau, A. Thabit, 2015, International journal of antimicrobial agents.

Synergistic Activity of Trovafloxacin and Ceftriaxone or Vancomycin against Streptococcus pneumoniae with Various Penicillin Susceptibilities

D. Nicolau, R. Quintiliani, C. Nightingale, 1998, Antimicrobial Agents and Chemotherapy.

Cost‐Effectiveness of Telavancin versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections

D. Nicolau, S. Barriere, J. Kuti, 2008, Pharmacotherapy.

Evaluation of a disease state management guideline for urinary tract infection.

D. Nicolau, M. Nailor, M. Zmarlicka, 2016, International journal of antimicrobial agents.

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.

D. Nicolau, T. Edeki, Shampa Das, 2015, The Journal of antimicrobial chemotherapy.

Imipenem/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-negative bacteria: a novel modelling approach for time-dependent killing

D. Nicolau, Kamilia Abdelraouf, A. Fratoni, 2023, The Journal of antimicrobial chemotherapy.

Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.

D. Nicolau, Aryun Kim, P. Koomanachai, 2009, The Journal of antimicrobial chemotherapy.

Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.

D. Nicolau, S. Kotapati, J. Kuti, 2005, Surgical infections.

Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.

Y. Carmeli, E. Goldstein, D. Nicolau, 2012, International journal of antimicrobial agents.

Bactericidal Efficacy of ABI-0043, a Novel Rifamycin, in a Murine Pneumococcal Pneumonia Model

D. Nicolau, S. Y. Lee, C. Murphy, 2006, The Journal of Antibiotics.

Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral.

D. Nicolau, R. Quintiliani, C. Nightingale, 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Prevalence of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut.

J. Quinn, D. Nicolau, C. Nightingale, 2004, Diagnostic microbiology and infectious disease.

Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration

J. Gonzales, D. Nicolau, Shailly Mehrotra, 2015, Antimicrobial Agents and Chemotherapy.

Making a Case for Pediatric Antimicrobial Stewardship Programs

D. Nicolau, Jennifer E. Girotto, N. Bennett, 2015, Pharmacotherapy.

Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States

D. Nicolau, Aryun Kim, J. Kuti, 2011, Mycoses.

Demography and burden of care associated with patients readmitted for urinary tract infection.

D. Nicolau, Shawn H. MacVane, Lindsay O Tuttle, 2015, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.

D. Nicolau, M. Villegas, G. Furtado, 2011, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia.

D. Nicolau, J. Kuti, S. Housman, 2011, Clinics in chest medicine.